

The Guidelines project was entirely supported by the European Glaucoma Society Foundation

AND  
FOR

# TERMINOLOGY GUIDELINES GLAUCOMA



**EUROPEAN GLAUCOMA SOCIETY**

[www.eugs.org](http://www.eugs.org)

4<sup>th</sup> Edition

Br J Ophthalmol: first published as 10.1136/bjophthalmol-2016-EGSGuideline.001 on 21 March 2017. Downloaded from <http://bjophthalmol.com/> on April 19, 2024 by guest. Protected by copyright.



**Supported by the EGS Foundation**

ISBN 978-88-98320-05-9



**PubliComm**

Piazza Guido Rossa 8r  
17100 Savona - Italy  
[www.publicomm.it](http://www.publicomm.it)

SvetPrint d.o.o.  
Printed in EU  
June 2014


Copyright © 2014 European Glaucoma Society

*No parts of this text, illustrations, tables or flowcharts can be reproduced, copied, translated or stored by any means including magnetic, electronic or multimedia formats without written permission of the European Glaucoma Society.*

AND  
FOR

# TERMINOLOGY GUIDELINES GLAUCOMA

4<sup>th</sup> Edition



**EUROPEAN GLAUCOMA SOCIETY**

[www.eugs.org](http://www.eugs.org)

The Guidelines project was entirely supported by the European Glaucoma Society Foundation



# Contents

	Page
<b>FOREWORD</b>	6
<b>INTRODUCTION CHAPTER</b>	11
<b>GLOSSARY</b>	27
<b>CHAPTER 1 - PATIENT EXAMINATION</b>	31
1.1 Intraocular pressure (iop) and tonometry	33
1.2 Gonioscopy	39
1.3 Optic nerve head and retinal nerve fibre layer	48
1.4 Perimetry	58
<b>CHAPTER 2 - CLASSIFICATION AND TERMINOLOGY</b>	73
2.1 Primary congenital forms/childhood glaucomas	75
2.2 Primary open-angle glaucomas	79
2.3 Secondary Glaucomas	90
2.4 Primary Angle-Closure	100
2.5 Secondary Angle-Closure	114
<b>CHAPTER 3 - TREATMENT PRINCIPLES AND OPTIONS</b>	129
3.1 General Principles of Glaucoma Treatment	131
3.2 Target IOP and Quality of Life	134
3.3 Antiglaucoma Drugs	139
3.4 Adherence, Compliance and Persistence in Glaucoma	159
3.5 Laser Surgery	161
3.6 Incisional Surgery	169
3.7 Cataract and Glaucoma Surgery	176
<b>INDEX</b>	192

# Foreword

It gives me pleasure to introduce the 4<sup>th</sup> edition of the EGS Guidelines. The Third edition proved to be extremely successful, being translated into 7 languages with over 70000 copies being distributed across Europe; it has been downloadable, free, as a pdf file for the past 4 years. As one of the main objectives of the European Glaucoma Society has been to both educate and standardize glaucoma practice within the EU, these guidelines were structured so as to play their part.

Glaucoma is a living specialty, with new ideas on causation, mechanisms and treatments constantly appearing. As a number of years have passed since the publication of the last edition, changes in some if not all of these ideas would be expected.

For this new edition of the guidelines a number of editorial teams were created, each with responsibility for an area within the specialty; updating where necessary, introducing new diagrams and Flowcharts and ensuring that references were up to date. Each team had writers previously involved with the last edition as well as newer and younger members being co-opted.

As soon as specific sections were completed they had further editorial comment to ensure cross referencing and style continuity with other sections.

Overall guidance was the responsibility of Anders Heijl and Carlo Traverso. Tribute must be made to the Task Force whose efforts made the timely publication of the new edition possible.

**Roger Hitchings**  
Chairman of the EGS Foundation

**The Guidelines Writers and Contributors**

Augusto Azuara Blanco  
Luca Bagnasco  
Alessandro Bagnis  
Keith Barton  
Christoph Baudouin  
Boel Bengtsson  
Alain Bron  
Francesca Cordeiro  
Barbara Cvenkel  
Philippe Denis  
Christoph Faschinger  
Panayiota Founti  
Stefano Gandolfi  
David Garway Heath  
Francisco Goñi  
Franz Grehn  
Anders Heijl  
Roger Hitchings  
Gábor Holló  
Tony Hommer  
Michele lester  
Jost Jonas  
Yves Lachkar  
Giorgio Marchini  
Frances Meier Gibbons  
Stefano Miglior  
Marta Misiuk-Hojto  
Maria Musolino  
Jean Philippe Nordmann  
Norbert Pfeiffer  
Luis Abegao Pinto  
Luca Rossetti  
John Salmon  
Leo Schmetterer  
Riccardo Scotti  
Tarek Shaarawy  
Ingeborg Stalmans  
Gordana Sunaric Mégevand  
Ernst Tamm  
John Thygesen  
Fotis Topouzis  
Carlo Enrico Traverso  
Anja Tuulonen  
Ananth Viswanathan  
Thierry Zeyen

**The Guidelines Task Force**

Luca Bagnasco  
Anders Heijl  
Carlo Enrico Traverso  
  
Augusto Azuara Blanco  
Alessandro Bagnis  
David Garway Heath  
Michele lester  
Yves Lachkar  
Ingeborg Stalmans  
Gordana Sunaric Mégevand  
Fotis Topouzis  
Anja Tuulonen  
Ananth Viswanathan

**The EGS Executive Committee**

Carlo Enrico Traverso  
*(President)*  
Anja Tuulonen  
*(Vice President)*  
Roger Hitchings  
*(Past President)*  
Anton Hommer  
*(Treasurer)*  
Barbara Cvenkel  
Julian Garcia Feijoo  
David Garway Heath  
Norbert Pfeiffer  
Ingeborg Stalmans

**The Board of the European Glaucoma Society Foundation**

Roger Hitchings *(Chair)*  
Carlo E. Traverso *(Vice Chair)*  
Franz Grehn  
Anders Heijl  
John Thygesen  
Fotis Topouzis  
Thierry Zeyen

**The EGS Committees**

**CME and Certification**

Gordana Sunaric Mégevand  
*(Chair)*  
Carlo Enrico Traverso  
*(Co-chair)*

**Delivery of Care**

Anton Hommer *(Chair)*

**EU Action**

Thierry Zeyen *(Chair)*  
Carlo E. Traverso *(Co-chair)*

**Education**

John Thygesen *(Chair)*  
Fotis Topouzis *(Co-chair)*

**Glaucomene**

Ananth Viswanathan *(Chair)*  
Fotis Topouzis *(Co-chair)*

**Industry Liaison**

Roger Hitchings *(Chair)*

**Information Technology**

Ingeborg Stalmans *(Chair)*  
Carlo E. Traverso *(Co-chair)*

**National Society Liaison**

Anders Heijl *(Chair)*

**Program Planning**

Fotis Topouzis *(Chair)*  
Ingeborg Stalmans *(Co-chair)*

**Quality and Outcomes**


Anja Tuulonen *(Chair)*  
Augusto Azuara Blanco  
*(Co-chair)*

**Scientific**

Franz Grehn *(Chair)*  
David Garway Heath  
*(Co-chair)*

For Conflict of interest/Financial disclosure please see [www.eugs.org/pdf/FinancialDisclosure.pdf](http://www.eugs.org/pdf/FinancialDisclosure.pdf)





# Introduction Chapter



# Introduction Chapter

The aim of these Guidelines is to present the view of the European Glaucoma Society (EGS) on the diagnosis and management of glaucoma. Our Guidelines are intended to support ophthalmologists in managing patients affected by, or suspected of having, glaucoma. The Guidelines should be considered as recommendations rather than as strict treatment protocols.

In the last edition, a simplified grading system for rating the strength of recommendation and the quality of evidence was introduced and has been retained in the present edition. The **strength of recommendation** is graded as either **I** (strong) or **II** (weak). A strong recommendation (I) is to be interpreted as “we recommend” and/or “very relevant in clinical practice” and a weak recommendation (II) as “we suggest” and/or “less relevant in clinical practice”.

The **quality of evidence** is classified as high (**A**), moderate (**B**), low (**C**) or very low (**D**). As an example, high quality evidence would be supported by high quality randomised clinical trials (RCTs). Observational studies would be typically graded as low-quality evidence. Consensus from our Panel would be graded as (D).

Clinical care must be individualised to the patient, the treating ophthalmologist and the socioeconomic milieu. The availability of Randomized Controlled Trials (RCTs) makes it possible to apply scientific evidence to clinical recommendations. Irrespective of the relative wealth of each European region, economical factors must be considered by physicians, in order to provide sustainable healthcare.

The EGS and all contributors disclaim responsibility and all liability for any adverse medical or legal effects resulting directly or indirectly from the use of any of the definitions, diagnostic techniques or treatments described in the Guidelines. The EGS does not endorse any product, procedure, company or organisation.

## I.1 Terminology, Classification and Definitions

Classification and disease definitions are arbitrary, and a consensus can be reached only if they are acceptable to most ophthalmologists on both theoretical and practical grounds. There are conditions where a precise classification is particularly challenging, such as in congenital forms associated with other anomalies.

The following factors are to be considered in order to identify and separate the different glaucoma categories.

1. Anatomy / Structure (See Ch. 1)  
Open-angle, closed-angle, optic nerve head, etc.  
e.g. clinical signs, exfoliation, pigment dispersion
2. Function (See Ch. 1)  
e.g. visual field
3. Intraocular pressure (IOP) level (See Ch. 1)
  - 3.1. At which diagnosis is made (See Ch. 2)
  - 3.2. At which damage occurred (See Ch. 1)
  - 3.3. Target IOP (See Ch. 3.2)<sup>12</sup>
  - 3.4. General conditions: life expectancy, comorbidities

**MISSION STATEMENT**

The goal of glaucoma treatment is to maintain the patient's visual function and related quality of life, at a sustainable cost. The cost of treatment in terms of inconvenience and side effects as well as financial implications for the individual and society requires careful evaluation (See Ch. 3). Quality of life is closely linked with visual function and, overall, patients with early to moderate glaucoma damage have good visual function and modest reduction in quality of life, while quality of life is considerably reduced if both eyes have advanced visual function loss.

**I.2 Treatment Principles**

- A.** Treatment Goals (See Ch. 3.1)
- A.1. Quality of life
  - A.2. Quality of vision
  - A.3. Cost containment
- B.** Suggested ways of reaching the goal (see Ch. 3 and 4)
- B.1.** Selection of patients to be treated
    - B.1.1.** Identification of patients with disease
    - B.1.2.** Identification of patients at risk of developing the disease [I,D]
      - B.1.2.1.** Identification of the clinical entity, possibly using a systematic classification (See Ch. 2)
      - B.1.2.2.** Consideration of mixed mechanisms
    - B.1.3.** Treatment of the above when actual or expected rate of decay risks interfering with quality of life [I,C]
  - B.2.** Decreasing the risk of ganglion cell loss since it reduces visual function
    - Determine the target IOP for the individual [I,D]. In general, when there is more advanced damage, lower IOPs are needed to prevent further progression [I,D]
    - IOP lowering [I,A]
      - Drugs
      - Laser
      - Surgery
    - Verify the target IOP (See Ch.3.2)
    - Monitor the Rate of Progression (Field and Disc) [I,D]
    - Adjust management according to ROP
    - Blood flow (see Ch. 1 and Ch. 3) or neuroprotection (See Ch. 3.); both under debate [II,D]
    - Consider always compliance, persistence and assiduity of follow-up
  - B.3.** Incorporation of a quality of life measure in the outcome of treatment
- C.** Audit outcomes e.g. efficacy, safety, cost [I,D] (See Ch. Introduction III)
- C.1.** Failures include patients suffering from the consequences of insufficient IOP lowering,

Since resources are limited worldwide, the following points are relevant to glaucoma treatment guidelines:

- prevention of visual disability in those at risk of decreased quality of life;
- avoid widespread treatment of elevated IOP per se;
- enforce effective treatment/follow-up in patients with severe functional loss and/or rapid progression;
- implement strategies to detect all patients with manifest disease.

These points are supported by the results of Randomized Clinical Trials for glaucoma (See Chapter Introduction II).

## FC I – Suggested Questions for Your Glaucoma Patient



### AT BASELINE

#### HISTORY/RISK FACTORS

##### SPECIFICALLY ENQUIRE ABOUT

- ALL MEDICATIONS
- FAMILY HISTORY (GENERAL/OPHTHALMOLOGICAL)
- CORTICOSTEROID THERAPY (TOPICAL/SYSTEMIC)
- OCULAR TRAUMA (CONTUSION)
- REFRACTIVE SURGERY
- CARDIOVASCULAR OR RESPIRATORY DISEASES/OTHER CHRONIC OR SEVERE DISEASES
- VASCULAR DISORDERS
- DRUGS ALLERGY




### DIRECT QUESTIONS AT FOLLOW-UP

- HOW ARE YOU?
- HOW DO YOU THINK YOUR EYES ARE DOING?
- DO YOU THINK YOUR CONDITION IS BETTER, STABLE OR WORSE?
- DO YOU HAVE DIFFICULTY WITH YOUR DAILY TASKS?
- DO YOU UNDERSTAND YOUR DIAGNOSIS?
- ARE THE GLAUCOMA MEDICATIONS INTERFERING WITH YOUR DAILY ACTIVITIES?
- ARE YOU WORRIED ABOUT YOUR EYES?
- HAVE YOU BEEN USING YOUR EYE DROPS AS PRESCRIBED?
- DO YOU ADMINISTER THE DROPS BY YOURSELF OR BY A RELATIVE?
- IF BY YOURSELF, PLEASE SHOW ME HOW YOU DO IT

PLEASE SHAKE HANDS WITH PATIENTS. BESIDES BEING KIND AND ENCOURAGING, YOU WILL FEEL THE TEMPERATURE OF THEIR PERIPHERAL SKIN.

## Evaluation of Functional Loss / Time for Individualized Treatment



© European Glaucoma Society 2014

**Figure 1.** Evaluation of functional loss/time for individualised treatment

**IOP** = the IOP level causing damage

**L** = the difference of visual function between the age-matched normal and the function at the time of diagnosis

**RoP** = angle between physiological loss and disease progression, representing progression rate

**T** = time interval between birth and the time of diagnosis

**FACTORS** = some of the individual features influencing clinical management (in alphabetical order):

1. Corneal thickness; 2. Family history; 3. Gonioscopy; 4. IOP, mean and fluctuation; 5. Life expectancy;
6. Pigment dispersion/exfoliation; 7. Rate of Progression (RoP); 8. Stage of optic nerve head (ONH) damage; 9. Stage of VF damage; 10. Systemic diseases

The EGS guidelines are to be adapted to individual patients, socioeconomic environment, medical facilities, skills of the average ophthalmologist and health professional, and to available resources

## II - RANDOMIZED CONTROLLED TRIALS FOR GLAUCOMA

In the following pages we briefly summarize results from the large randomized glaucoma trials (RCTs, and derive comments relevant to clinical decision-making).

### II.1 Treatment Vs No Treatment Trials

#### II.1.1 Collaborative Normal Tension Glaucoma Study (CNTGS)

CNTGS compared treatment versus no treatment in normal tension glaucoma. Eligible patients had verified progression or threat to fixation. The primary outcome measure was disease progression as evident from visual fields or stereo disk photographs. 140 patients were randomized. The treatment goal was a 30% reduction from baseline IOP, obtained with medications. In patients undergoing surgery a 20% reduction was accepted.

Summary of results<sup>1-5</sup>: A 30% reduction from baseline was maintained in nearly 50% of patients. Progression occurred in 12% (7/61) of treated eyes and 35% (28/79) of controls.

- A beneficial effect of IOP lowering was found only after the data were censored for the effect on VF of cataract formation<sup>1</sup>
- In the intent-to-treat analysis no benefit of treatment was found<sup>2</sup>
- Cataracts were more common in patients treated with surgery
- No correlation with IOP levels maintained during follow up was found in either group
- Progression rates varied a lot. The mean progression rate in the untreated arm was 0.41 dB/year<sup>5</sup>. Prior documented progression did not increase the risk of future progression compared to subjects without such history

#### II.1.2 Early Manifest Glaucoma Trial (EMGT)

EMGT was a randomized, prospective trial comparing treatment versus no treatment to evaluate the effectiveness of IOP reduction in early, previously untreated open-angle glaucoma<sup>6</sup>. Secondary aims were to assess factors related to glaucoma progression, and to determine the natural history of the disease.

During a population-based screening among 44,243 residents in Sweden, 316 eyes of 255 patients were recruited.

Treated patients received a standardized treatment protocol of laser trabeculoplasty and topical betaxolol. Treatment or no-treatment remained unchanged as long as definite progression had not occurred. Primary outcome measure was progression of disease, defined by sustained increases of visual field loss or optic disc changes<sup>6</sup>.

Summary of results<sup>7-12</sup>: This study proves and quantifies the value of IOP reduction in patients with POAG, NTG and pseudoexfoliation glaucoma.

- A 25% decrease of IOP from baseline (mean untreated IOP 20.6 mmHg) reduced the risk of progression by 50%. Risk of progression decreased 10% with each mmHg IOP reduction from baseline to the first follow-up visit<sup>7</sup>
- Risk of progression was smaller with lower baseline IOP values and with a larger initial IOP drop induced by treatment<sup>8</sup>
- IOP reduction for the fixed treatment protocol, and for ALT depended very much on pre-treatment IOP<sup>13,14</sup>
- Important risk factors for progression were: higher IOP, exfoliation syndrome, more baseline damage, higher age, disc haemorrhages, thinner CCT (in HTG), and low blood pressure (in NTG)<sup>10</sup>
- IOP fluctuation was not a risk factor for progression<sup>11</sup>
- IOP did not increase but remained constant over time in untreated eyes with POAG, but increased over time in eyes with exfoliation glaucoma<sup>15</sup>
- Increase in lens opacity occurred more in the treatment arm than in the control arm<sup>7</sup>
- Disease progression rates varied substantially between individual patients.
- Untreated progression rates (natural history) were slower in NTG than in HTG, while eyes with exfoliation glaucoma progressed much faster<sup>16</sup>
- Progression criteria were more sensitive than those of AGIS and CIGTS, and definite progression was associated with a mean worsening of MD of less than 2dB<sup>17</sup>
- In the great majority of cases progression was found first by perimetry<sup>7</sup>
- QoL did not differ between treatment arms<sup>9</sup>
- The frequency of disc haemorrhages was higher with lower IOP and was not influenced by treatment<sup>18</sup>

### II.1.3 The Ocular Hypertension Treatment Study (OHTS)

The OHTS was a multicentre, randomized, prospective clinical trial, designed to study the effect of topical ocular hypotensive medication in delaying or preventing the onset of glaucoma in patients with ocular hypertension (OH)<sup>19</sup>. 1,636 patients were recruited. Randomization was between treatment with IOP lowering medications and no treatment. The treatment goal was to lower the IOP to < 24 mmHg and at least 20% from baseline. The primary outcome was the development of primary open-angle glaucoma defined as reproducible visual field defects or reproducible optic disc deterioration. After the initial results were reported, also the control group received treatment.

Summary of results: Mean IOP reduction was 22.5% in the treated group, but also the control group showed decrease of IOP, 4.0%

- After 5 years 4.4% of patients in the treated group had developed signs of glaucoma damage versus 9% in controls ( $p < 0.0001$ ), a 50% reduction of risk<sup>20</sup>
- Thus > 90% of untreated patients had not converted to glaucoma after 5 years
- After 13 years 22% of patients who had initially been randomized to the control group had converted to glaucoma versus 16% in the group that was treated already at the start of the study<sup>21</sup>
- POAG conversion was detected first in disc photographs in around 50% of patients and by field testing in approximately 40%<sup>22</sup>

- Risk factors for progression were: thinner CCT, higher IOP, disc haemorrhages, older age, larger vertical and horizontal cup-to-disc ratios, greater PSD
- Disc haemorrhages detectable in photographs had been missed at 87% of clinical examinations and rate of progression was higher in eyes with haemorrhages<sup>23</sup>
- Cataract formation was more common in the medication group<sup>24</sup>
- Results obtained from initially untreated patients who were later started on prostaglandins indicate that monocular trials (at least of prostaglandin drops) may have very limited value<sup>25</sup>
- Retinal vein occlusions were uncommon but somewhat more common in the control group (2.1%) than in the treated group (1.4%), not statistically significant<sup>26</sup>.

#### II.1.4 European Glaucoma Prevention Study (EGPS)

The EGPS was a multicentre, randomized, double-masked, placebo-controlled clinical trial. The aim of this study was to evaluate the efficacy of IOP reduction by dorzolamide in preventing glaucoma damage in patients with OH. The patients were randomized into 2 groups: active therapy (dorzolamide) and placebo. Main outcome measures were visual field and/or optic disc changes<sup>27</sup>.

Summary of results<sup>28</sup>: 1,081 patients were enrolled. The median duration of follow-up was 55 months. The IOP difference between the treatment and the control group was small. The mean IOP reduction was 15% after 6 months and 22% after 5 years in the dorzolamide group, but there was also a 9% reduction after 6 months and 19% after 5 years in the placebo group, to a large part attributable to high attrition.

The study failed to detect a statistically significant difference between the chosen medical therapy and placebo, either in IOP lowering effect, or in the rate of progression to POAG, and attrition was large<sup>28</sup>.

The same predictors for the development of POAG were identified independently in both the OHTS observation group and the EGPS placebo group-baseline older age, higher intraocular pressure, thinner CCT, larger vertical cup-to-disc ratio, and higher Humphrey VF pattern standard deviation<sup>29</sup>.

In a later paper diuretics were pointed as a possible risk factor<sup>30</sup>.

## II.2 Studies Comparing Treatments

### II.2.1 Collaborative Initial Glaucoma Treatment Study (CIGTS)

The aim was to find out if glaucoma is better treated by initial treatment with medications or by immediate filtration surgery<sup>31</sup>.

607 patients with newly diagnosed open-angle glaucoma randomized to initial treatment with either medication or trabeculectomy (with or without 5-fluorouracil). A target IOP algorithm was used specific for each individual eye. Primary outcome variables were VF progression and Quality of Life (QoL). Secondary outcome variables were Visual Acuity (VA), IOP, and cataract formation. No event analysis has been provided identifying numbers of progressing eyes.

Summary of results<sup>32-34</sup>: IOP reduction was larger with surgery (48%; mean post treatment IOP 14-15 mmHg;) than with medications (35%; mean post treatment IOP 17-18 mmHg)<sup>35</sup>.

- For many years mean perimetric progression (analysed as mean MD among all subjects) was small in both groups<sup>32</sup>, but after 8 years 21% of surgical patients and 25% of medical patient had progressed, defined as a worsening of MD by 3 dBs<sup>35</sup>.
- After adjustment for baseline risk factors, larger IOP variation measures were associated with significantly worse MD values after 3 to 9 years in the medicine but not in the surgical group<sup>36</sup>.
- QoL was initially better in the medically treated group<sup>37</sup>.
- 1.1% of surgical patients had developed endophthalmitis after 5 years<sup>38</sup>.
- Patients randomized to the surgery arm underwent cataract surgery more than twice as often as patients in the medical treatment group<sup>33</sup>.
- Reversal of optic disc cupping was seen in 13% in the surgical group, but was not associated with improved visual function<sup>39</sup>.
- Risk factors for progression have not been reported in a ways similar to that of the other large RCTs, but risk factors for higher IOP have been, and included higher baseline IOP, worse field status and lower level of education<sup>34</sup>.

Inclusion criteria may have allowed recruitment of patients with ocular hypertension resulting in a case mix with a smaller risk of showing progression.

### II.2.2 Advanced Glaucoma Intervention Study (AGIS)

AGIS was a multicentre, prospective randomized study in patients with advanced open-angle glaucoma patients who could not be controlled by maximum tolerated medical therapy alone. 591 patients (789 eyes) were randomised between two rather complicated treatments regimes:

1. ATT: argon laser trabeculoplasty then if needed followed by trabeculectomy and then by a 2<sup>nd</sup> trabeculectomy, or
2. TAT: trabeculectomy then argon laser trabeculoplasty if needed, and then trabeculectomy.

Enrolled eyes had consistent elevation of intraocular pressure (IOP) of  $\geq 18$  mmHg. Patients with MD worse than 16 dB were excluded thus excluding eyes with really advanced glaucoma as in several of the other RCTs<sup>40</sup>.

Summary of results:

- In a post-hoc analysis of patients with 6-years of follow-up or more a eyes with average IOP  $> 17.5$  mmHg over the first three 6-months visits showed a significantly more/more frequent visual field deterioration compared to eyes with IOP less than 14 mmHg during the same time. There was no average visual field progression, as measured by MD, in eyes with IOP  $< 18$  mmHg at 100% of the visits, whereas eyes with less perfect IOP control showed a mean significant visual field worsening<sup>41</sup>
- After 7 years mean reduction of IOP was greater for eyes assigned to the TAT protocol, and the cumulative probability of failure of the first intervention was greater for eyes assigned to ATT
- The percentage of eyes with decreased visual acuity or visual field progression was lower for the ATT sequence than for TAT In Afro-American patients, but in Caucasians results were more favourable in the ATT during the first 4 years, but then switched in favour of TAT<sup>42,43</sup>
- The probability of cataract formation after 5 years was high after trabeculectomy, 78 %<sup>35</sup>. Initial trabeculectomy retarded the progression of glaucoma more effectively in Caucasians than in Afro-Americans<sup>44</sup>
- Risk factors associated with progression were older age, longer follow-up, and, not surprisingly, increasing number of glaucoma interventions<sup>45</sup>
- A flawed analysis erroneously indicated that IOP fluctuations were a risk factor for progression<sup>45</sup>, while a later corrected indicated that such fluctuations were a risk in NTG only<sup>46</sup>
- Both ALT and trabeculectomy failed more often in younger patients and in eyes with higher pre-treatment IOP AGIS investigators<sup>47</sup>

### II.3 Summary

These large RCTs have had enormous importance for glaucoma management. EMGT and OHTS are the first studies that without doubt showed that IOP reduction reduces rate of progression in manifest glaucoma and the incidence of glaucoma in ocular hypertension. In addition the RCTs show that IOP reduction reduces progression also in glaucoma eyes with normal IOP levels, and that risk reduction with IOP lowering is large; several of the studies show risk reductions of approximately 10% for every mmHg lower pressure.

Together they also identify the important factors for progression, in glaucoma, e.g., older age, higher IOP, more damage, pseudoexfoliation and disc haemorrhages, in ocular hypertension higher IOP, older age, thinner CCT and disc haemorrhages.

The RCTs have demonstrated the value of glaucoma treatment, resulted in more ambitious treatment and provided a much more solid foundation for evidence-based glaucoma care.

### III - COST-EFFECTIVENESS OF GLAUCOMA CARE

#### III.1 Case Detection And Screening for Glaucoma

There are no systematic reviews or studies that provide evidence for direct or indirect links between glaucoma screening and visual field loss, visual impairment, optic nerve damage, intraocular pressure, or patient-reported outcomes. Also economic simulation models of cost effectiveness of screening report inconclusive results with large uncertainties<sup>48-52</sup>. There is no evidence that interventions (e.g., training) improve opportunistic case finding<sup>52-54</sup>.

#### III.2 Clinical and Cost Effectiveness of Diagnostic Tests Used for Screening, Detection and Monitoring for Glaucoma

No randomized screening, diagnostic and follow-up trials reporting the clinical effectiveness or cost-effectiveness have been published<sup>48, 50, 51, 55</sup>. Although there are numerous comparative diagnostic studies there is no evidence which test or combination of tests improve patient outcomes at a sustainable cost. There is a high degree of variability in the design and conduct of largely cross-sectional studies of diagnostic accuracy of technologies for glaucoma. Diagnostic studies typically compare the performance of a small number of technologies, and indirect comparisons with other tests have to be interpreted with caution (e.g., because of differences in population, study definitions, reference standard, etc.). The risk of bias of diagnostic study designs is an additional concern<sup>48, 50, 51, 55</sup>. One of the major challenges to evaluate a diagnostic test in glaucoma is the lack of a perfect reference standard. There are multiple diagnostic technologies that can be potentially used to detect glaucoma. Diagnostic studies have been conducted in a variety of settings (e.g., screening, case detection in the community, and diagnosis at hospital eye services).

#### III.3 Treatment of Glaucoma and Ocular Hypertension in Preventing Visual Disability

There is high-level evidence that treatment (including medical, laser, and surgical treatments) decrease intraocular pressure and reduce the risk of development (e.g., in patients with OHT) and deterioration (i.e., in patients with established glaucoma) of optic nerve damage and visual field loss compared to no treatment. However, the direct effects of treatments on visual impairment and the comparative efficacy of different treatments are not clear. Which treatments improve patient-reported outcomes is also unclear<sup>56</sup>. Based on the economic simulation models in the US, UK, Holland, and China, treating glaucoma appears to be cost effective compared to 'no treatment'. There is uncertainty whether to treat none, some or all patients with ocular hypertension<sup>48, 57-59</sup>. When treated, the cost-effectiveness models of different therapeutic interventions give variable results<sup>48</sup>.

### Comment:

All published simulation models are based on characteristics of participants enrolled in relatively small and tight randomized controlled trials (RCTs) which may not include all important predictors in the general population and every-day practice. In addition, RCTs may give an optimistic impression of outcomes compared to 'real life' with poorer compliance and adherence to care both in patients and clinicians in implementing the guide lines and care protocols. As the data of glaucoma induced visual disability are limited, the blindness rates in the modeling studies have different estimates<sup>48</sup>. Similarly, the data on utility values and influence of glaucoma severity in health status are limited. Retrospective observational data is incomplete and selective. Reliable and 'realistic' data (preferably from large randomized trials or prospective cohorts of 'usual patients') is not available so far<sup>48</sup>.

### **III.4 Follow-Up Protocols And Models Of Care**

There is no solid evidence of the optimum monitoring schemes, (e.g. frequency and timing of visits, technologies to be used for detecting progression) for patients with manifest glaucoma and ocular hypertension. Some modeling and retrospective studies suggest that more treatment may allow less frequent monitoring visits in ocular hypertension and stable glaucoma<sup>57, 59-61</sup>. One RCT suggests that shared care may save costs<sup>62</sup>.

## References

1. Group CN-TGS. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. *Am J Ophthalmol* 1998;126(4):487-97.
2. Group CN-TGS. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. . *Am J Ophthalmol* 1998;126(4):498-505.
3. Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. *Am J Ophthalmol* 2001;131(6):699-708.
4. Anderson DR, Drance SM, Schulzer M. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. *Am J Ophthalmol* 2003;136(5):820-9.
5. Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. *Ophthalmology* 2001;108(2):247-53.
6. Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. *Ophthalmology* 1999;106(11):2144-53.
7. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol* 2002;120(10):1268-79.
8. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. *Arch Ophthalmol* 2003;121(1):48-56.
9. Hyman LG, Komaroff E, Heijl A, et al. Treatment and vision-related quality of life in the early manifest glaucoma trial. *Ophthalmology* 2005;112(9):1505-13.
10. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. *Ophthalmology* 2007;114(11):1965-72.
11. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. *Ophthalmology* 2007;114(2):205-9.
12. Heijl A, Leske MC, Bengtsson B, Hussein M. Measuring visual field progression in the Early Manifest Glaucoma Trial. *Acta Ophthalmol Scand* 2003;81(3):286-93.
13. Heijl A, Leske MC, Hyman L, et al. Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial. *Acta Ophthalmol* 2011;89(8):749-54.
14. Heijl A, Peters D, Leske MC, Bengtsson B. Effects of argon laser trabeculoplasty in the Early Manifest Glaucoma Trial. *Am J Ophthalmol* 2011;152(5):842-8.
15. Hyman L, Heijl A, Leske MC, et al. Natural history of intraocular pressure in the early manifest glaucoma trial: A 6-year follow-up. *Arch Ophthalmol* 2010;128(5):601-7.
16. Heijl A, Bengtsson B, Hyman L, Leske MC. Natural history of open-angle glaucoma. *Ophthalmology* 2009;116(12):2271-6.
17. Heijl A, Bengtsson B, Chauhan BC, et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. *Ophthalmology* 2008;115(9):1557-65.
18. Bengtsson B, Leske MC, Yang Z, Heijl A. Disc hemorrhages and treatment in the early manifest glaucoma trial. *Ophthalmology* 2008;115(11):2044-8.
19. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. *Arch Ophthalmol* 1999;117(5):573-83.
20. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol* 2002;120(6):701-13; discussion 829-30.
21. Kass MA, Gordon MO, Gao F, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. *Arch Ophthalmol* 2010;128(3):276-87.

22. Keltner JL, Johnson CA, Anderson DR, et al. The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study. *Ophthalmology* 2006;113(9):1603-12.
23. Budenz DL, Anderson DR, Feuer WJ, et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. *Ophthalmology* 2006;113(12):2137-43.
24. Herman DC, Gordon MO, Beiser JA, et al. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. *Am J Ophthalmol* 2006;142(5):800-10.
25. Bhorade AM, Wilson BS, Gordon MO, et al. The utility of the monocular trial: data from the ocular hypertension treatment study. *Ophthalmology* 2010;117(11):2047-54.
26. Barnett EM, Fantin A, Wilson BS, et al. The incidence of retinal vein occlusion in the ocular hypertension treatment study. *Ophthalmology* 2010;117(3):484-8.
27. Miglior S, Zeyen T, Pfeiffer N, et al. The European glaucoma prevention study design and baseline description of the participants. *Ophthalmology* 2002;109(9):1612-21.
28. Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European Glaucoma Prevention Study. *Ophthalmology* 2005;112(3):366-75.
29. Miglior S, Pfeiffer N, Torri V, et al. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. *Ophthalmology* 2007;114(1):3-9.
30. Miglior S, Torri V, Zeyen T, et al. Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. *Am J Ophthalmol* 2007;144(2):266-75.
31. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. *Ophthalmology* 1999;106(4):653-62.
32. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. *Ophthalmology* 2001;108(11):1943-53.
33. Musch DC, Gillespie BW, Niziol LM, et al. Cataract extraction in the collaborative initial glaucoma treatment study: incidence, risk factors, and the effect of cataract progression and extraction on clinical and quality-of-life outcomes. *Arch Ophthalmol* 2006;124(12):1694-700.
34. Musch DC, Gillespie BW, Niziol LM, et al. Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study. *Ophthalmology* 2008;115(6):927-33.
35. Musch DC, Gillespie BW, Lichter PR, et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. *Ophthalmology* 2009;116(2):200-7.
36. Musch DC, Gillespie BW, Niziol LM, et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. *Ophthalmology* 2011;118(9):1766-73.
37. Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. *Ophthalmology* 2001;108(11):1954-65.
38. Zahid S, Musch DC, Niziol LM, Lichter PR. Risk of endophthalmitis and other long-term complications of trabeculectomy in the Collaborative Initial Glaucoma Treatment Study (CIGTS). *Am J Ophthalmol* 2013;155(4):674-80, 80 e1.

39. Parrish RK, 2nd, Feuer WJ, Schiffman JC, et al. Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. *Am J Ophthalmol* 2009;147(4):717-24 e1.
40. Brown RH, Lynch M, Leef D, et al. The Advanced Glaucoma Intervention Study (Agis) .1. Study Design and Methods and Base-Line Characteristics of Study Patients. *Controlled Clinical Trials* 1994;15(4):299-325.
41. Investigators TA. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. *Am J Ophthalmol* 2000;130(4):429-40.
42. Ederer F, Gaasterland DA, Dally LG, et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. *Ophthalmology* 2004;111(4):651-64.
43. Investigators TA. The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. . *Arch Ophthalmol* 2000;118(12):1639-52.
44. (AGIS) TAGIS. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. *Am J Ophthalmol* 2001;132(3):311-20.
45. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. *Ophthalmology* 2004;111(9):1627-35.
46. Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. *Ophthalmology* 2008;115(7):1123-9 e3.
47. (AGIS) TAGIS. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. *Am J Ophthalmol* 2002;134(4):481-98.
48. Tuulonen A. Economic considerations of the diagnosis and management for glaucoma in the developed world. *Curr Opin Ophthalmol* 2011;22(2):102-9.
49. Vaahoranta-Lehtonen H, Tuulonen A, Aronen P, et al. Cost effectiveness and cost utility of an organized screening programme for glaucoma. *Acta Ophthalmol Scand* 2007;85(5):508-18.
50. Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. *Health Technol Assess* 2007;11(41):iii-iv, ix-x, 1-190.
51. Ervin AM, Boland MV, Myrowitz EH, et al. *Screening for Glaucoma: Comparative Effectiveness*. Rockville (MD)2012.
52. Taylor HR, Crowston, J., Keeffe, J. et al. Tunnel vision: the economic impact of primary open angle glaucoma – a dynamic economic model. Melbourne: Centre for Eye Research Australia, 2008. [www.cera.org.au](http://www.cera.org.au).
53. Ratnarajan G, Newsom W, French K, et al. The impact of glaucoma referral refinement criteria on referral to, and first-visit discharge rates from, the hospital eye service: the Health Innovation & Education Cluster (HIEC) Glaucoma Pathways project. *Ophthalmic Physiol Opt* 2013;33(2):183-9.
54. Shah S, Murdoch IE. NICE - impact on glaucoma case detection. *Ophthalmic Physiol Opt* 2011;31(4):339-42.
55. Tarride JE, Burke N, Hopkins RB, et al. New glaucoma diagnostic technologies: a systematic review of economic studies. *Can J Ophthalmol* 2011;46(1):89-90.
56. Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force.

- Ann Intern Med 2013;158(4):271-9.
57. Burr JM, Botello-Pinzon P, Takwoingi Y, et al. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. *Health Technol Assess* 2012;16(29):1-271, iii-iv.
  58. Li EY, Tham CC, Chi SC, Lam DS. Cost-effectiveness of treating normal tension glaucoma. *Invest Ophthalmol Vis Sci* 2013;54(5):3394-9.
  59. van Gestel A. Glaucoma management. Economic evaluations based on a patient level simulation model. Enschede, Holland: Ipskamp Drukkers, 2012.
  60. Hagman J. Comparison of resource utilization in the treatment of open-angle glaucoma between two cities in Finland: is more better? *Acta Ophthalmol* 2013;91 Thesis 3:1-47.
  61. Crane GJ, Kymes SM, Hiller JE, et al. Accounting for costs, QALYs, and capacity constraints: using discrete-event simulation to evaluate alternative service delivery and organizational scenarios for hospital-based glaucoma services. *Med Decis Making* 2013;33(8):986-97.
  62. Holtzer-Goor KM, van Sprundel E, Lemij HG, et al. Cost-effectiveness of monitoring glaucoma patients in shared care: an economic evaluation alongside a randomized controlled trial. *BMC Health Serv Res* 2010;10:312.




**GLOSSARY**

<b>5-FU</b>	5-Fluorouracil
<b>AAC</b>	Acute Angle-Closure
<b>AC</b>	Anterior Chamber
<b>AGIS</b>	Advanced Glaucoma Intervention Study
<b>ALPI</b>	Argon Laser Peripheral Iridoplasty
<b>ALT</b>	Argon Laser Trabeculoplasty
<b>APAC</b>	Anterior Chamber Paracentesis
<b>BAC</b>	Benzalkonium Chloride
<b>CACG</b>	Chronic Angle-Closure Glaucoma
<b>CAM</b>	Complementary And Alternative Medicine
<b>CCT</b>	Central Corneal Thickness
<b>CDR</b>	Cup/Disc Ratio
<b>CH</b>	Corneal Hysteresis
<b>CIGTS</b>	Initial Glaucoma Treatment Study
<b>CNS</b>	Central Nervous System
<b>CNTGS</b>	Collaborative Normal Tension Glaucoma Study
<b>COPD</b>	Chronic obstructive Pulmonary Disease
<b>CRF</b>	Corneal Resistance Factor
<b>DCT</b>	Dynamic contour tonometry
<b>DD</b>	Diffuse Defect
<b>ECC</b>	Enhanced Corneal Compensation
<b>EGPS</b>	European Glaucoma Prevention Study
<b>EGS</b>	European Glaucoma Society
<b>EMA</b>	The European Medicines Agency
<b>EMGT</b>	Early Manifest Glaucoma Trial
<b>FC</b>	Flow Chart
<b>FD</b>	Fourier-domain
<b>FDA</b>	Food and Drug Administration
<b>FDT</b>	Frequency Doubling Technology
<b>FL</b>	Fixation Losses
<b>FN</b>	False Negatives
<b>FP</b>	False Positive
<b>GAPS</b>	Glaucoma Adherence and Persistency Study
<b>GAT</b>	Goldmann Applanation Tonometry
<b>GHT</b>	The Glaucoma Hemifield Test
<b>GON</b>	Glaucomatous Optic Neuropathy
<b>GPA</b>	Glaucoma Progression Analyses
<b>GPS</b>	Glaucoma Probability Score
<b>GSL</b>	Goniosynechialysis
<b>GSS</b>	Glaucoma Staging System
<b>HEP</b>	Heidelberg Edge Perimetry
<b>HIV</b>	Human Immunodeficiency Virus
<b>HPG</b>	High Pressure Glaucoma
<b>HRP</b>	High-pass Resolution Perimetry
<b>HRT</b>	Heidelberg Retina Tomography

<b>HSV</b>	Herpes Simplex Virus
<b>IAC</b>	Intermittent Angle-Closure
<b>ICE</b>	Irido-Corneal Endothelial syndrome
<b>IDDM</b>	Insulin Dependent Diabetes Mellitus
<b>IOL</b>	Intraocular Lens
<b>IOP</b>	Intraocular Pressure
<b>ISNT</b>	Inferior-Superior-Nasal-Temporal rule
<b>ITC</b>	Iridotrabecular Contact
<b>LPI</b>	Laser Peripheral Iridotomy
<b>LR</b>	Likelihood Ratio
<b>LD</b>	Localized Defect
<b>LTP</b>	Laser Trabeculoplasty
<b>LV</b>	Loss Variance
<b>MAO</b>	Monoamine Oxidase
<b>MD</b>	Mean Defect
<b>MMC</b>	Mitomycin C
<b>MRA</b>	Moorfields Regression Analysis
<b>NCT</b>	Non-Contact Tonometry
<b>NF-1</b>	Neurofibromatosis type 1
<b>NF-2</b>	Neurofibromatosis type 2
<b>NFI</b>	Nerve Fibre Indicator
<b>NMDA</b>	N-Methyl-D-Aspartate
<b>NPG</b>	Normal Pressure Glaucoma
<b>OAG</b>	Open Angle Glaucoma
<b>OCT</b>	Optical Coherence Tomography
<b>OH</b>	Ocular Hypertension
<b>OHTS</b>	The Ocular Hypertension Treatment Study
<b>ON</b>	Optic Nerve
<b>ONH</b>	Optic Nerve Head
<b>OPA</b>	Ocular Pulse Amplitude
<b>ORA</b>	Ocular Response Analyser
<b>OSD</b>	Ocular Surface Disease
<b>PAC</b>	Primary Angle-Closure
<b>PACG</b>	Primary Angle-Closure Glaucoma
<b>PACS</b>	Primary Angle-Closure Suspect
<b>PAS</b>	Peripheral Anterior Synechiae
<b>PCG</b>	Primary Congenital Glaucoma
<b>PC-IOL</b>	Anteriorly Dislocated Posterior Chamber Intraocular Lens
<b>PCL</b>	Posterior Chamber Intraocular Lens
<b>PDS</b>	Pigment Dispersion Syndrome
<b>PDT</b>	Photo Dynamic Therapy
<b>PEX</b>	Pseudoexfoliation
<b>PFV</b>	Persistent Fetal Vasculature
<b>PG</b>	Pigmentary Glaucoma
<b>PG</b>	Prostaglandin
<b>PI</b>	Peripheral Iridotomy
<b>PIOL</b>	Phakic Intraocular Lens

<b>POAG</b>	Primary Open-Angle Glaucoma
<b>POH</b>	Pigmentary Ocular Hypertension
<b>PPT</b>	Pressure-Phosphene Tonometer
<b>PSD</b>	Pattern Standard Deviation
<b>RCT</b>	Randomized Controlled Trial
<b>RNFL</b>	Retinal Nerve Fiber Layer
<b>RT</b>	Rebound Tonometer
<b>SAP</b>	Standard Automated Perimetry
<b>SD</b>	Standard Deviation
<b>SITA</b>	Swedish Interactive Threshold Algorithm
<b>SLT</b>	Selective Laser Trabeculoplasty
<b>SPK</b>	Superficial Punctate Keratitis
<b>SWAP</b>	Short Wavelength Automated Perimetry
<b>TCA</b>	Topographic Change Analysis
<b>TDO</b>	Time Domain
<b>TM</b>	Trabecular Meshwork
<b>UBM</b>	Ultrasound Biomicroscopy
<b>UGH</b>	Uveitis-Glaucoma-Hyphema Syndrome
<b>VEGF</b>	Vascular Endothelial Growth Factor
<b>VF</b>	Visual Field
<b>VFI</b>	Visual Field Index
<b>VZV</b>	Varicella Zoster Virus
<b>XFG</b>	Exfoliative Glaucoma
<b>XFS</b>	Exfoliation Syndrome
<b>YAG</b>	Yttrium-Aluminium-Garnet



A stylized, semi-transparent illustration of a human eye is centered on the page. A hand is shown pointing towards the pupil of the eye. The background features a grid of small dots and various overlapping shapes in shades of gray and green.

## CHAPTER 1

# Patient Examination



## 1.1 - INTRAOCULAR PRESSURE (IOP) AND TONOMETRY

The intraocular pressure (IOP) in the population is approximately normally distributed with a right skew. The mean IOP in normal adult populations is estimated at 15-16 mmHg, with a standard deviation of nearly 3.0 mmHg<sup>1-10</sup>. Traditionally, normal IOP has been defined as two standard deviations above normality, i.e. 21 mmHg, and any IOP above this level is considered to be elevated. The level of IOP is a major risk factor for the development of glaucoma and its progression. For example, the risk of having glaucoma for those with IOP measurements of 26 mmHg or greater is estimated to be 12 times higher than that for those with IOP within the normal range<sup>1</sup>.

IOP diurnal variations can be substantial and are larger in glaucoma patients than in healthy individuals. Evaluating the IOP at different times of the day can be useful in selected patients [11,D].

### 1.1.1 Methods of measurement (tonometry)

Tonometry is based on the relationship between the intraocular pressure and the force necessary to deform the natural shape of the cornea by a given amount (except Dynamic Contour Tonometry, see below). Corneal biomechanical properties, such as thickness and elasticity, can affect the IOP measurements (Table 1.1). Tonometers can be described as contact or non-contact. Some instruments are portable and hand-held (e.g., Icare, Tonopen).

#### 1.1.1.1 Goldmann applanation tonometry (GAT)

The most frequently used instrument, and the current reference standard [11,D], is the Goldmann applanation tonometer (GAT), mounted at the slit lamp<sup>11</sup>. The method involves illumination of the biprism tonometer head with a blue light (obtained using a cobalt filter) that is used to flatten the anaesthetised cornea which has fluorescein in the tear film. The scaled knob on the side of the instrument is then turned until the inner border of the two hemi-circles of fluorescent tear meniscus, visualized through each prism, just touch (Fig. 1.1). There are potential problems of using GAT in that contact with the tear film and the cornea may raise concerns regarding transmissible disease. Chemical disinfection and disposable tonometer heads are used with the hope to reduce the risk of cross infection [11,D].

Errors with GAT can be due to incorrect technique (Fig. 1.2) and to the biological variability of the eye and orbit. Of particular note is the influence of the central corneal thickness (CCT). A tight collar or tie, Valsalva's manoeuvre, breath-holding, squeezing the lids or the examiner touching the lids can all falsely increase the IOP reading.

### 1.1.1.2 Alternative tonometers (in alphabetical order):

Table 1.2 below summarises the comparisons of IOP between other tonometers and GAT. A substantial proportion of IOP results differ by more than 2 mmHg<sup>12</sup>. A complete list of all available technologies is beyond the scope of the guidelines.

- Dynamic contour tonometry (DCT, or Pascal)  
This slit-lamp mounted instrument contains a sensor tip with concave surface contour and a miniaturized pressure sensor. The result and a quality score measure are provided digitally. This technique is reportedly less influenced by corneal thickness than GAT. The DCT additionally measures the ocular pulse amplitude (OPA) which is the difference between the mean systolic and the mean diastolic IOP<sup>13-18</sup>.
- Non-contact tonometry (NCT)  
The NCT or air puff tonometry uses a rapid air pulse to flatten the cornea, thus working on the same basic principle as the Goldmann tonometer. The advantages include speed, no need for topical anaesthesia and no direct contact with the eye. There are several models available in the market. Some patients have found the air puff uncomfortable. There is currently insufficient evidence to replace GAT with non-contact tonometry<sup>19, 20</sup>.
- Ocular Response Analyser (ORA)  
The ORA utilises air-puff technology to record two applanation measurements, one while the cornea is moving inward, and the other as the cornea returns. The average of these two IOP values provides a Goldmann-correlated IOP measurement (IOP<sub>G</sub>). The difference between these two IOP readings is called Corneal Hysteresis (CH), a result of viscous damping in the corneal tissue. The CH measurement provides a basis for two additional new parameters: Corneal-Compensated Intraocular Pressure (IOP<sub>CC</sub>) and Corneal Resistance Factor (CRF). The IOP<sub>CC</sub> is a measurement that is less affected by the corneal properties. Four good quality readings per eye are recommended<sup>21-25</sup> [II,D].
- Ocuton S  
The Ocuton S is a self-measurement applanation tonometer that calculates and displays the IOP value automatically through direct contact of the measuring prism with the cornea. Topical anaesthetic is required<sup>26, 27</sup>.
- Pneumatometry  
The pneumatometer relies on the Mackay-Marg principle and measures intraocular pressure noninvasively through applanation tonometry<sup>28</sup>. The sensing unit of the pneumatometer, covered with a Silastic diaphragm, pressurized air flows constantly through an opening centrally into the space between the nozzle and the diaphragm. When in contact with the cornea, the pressure of the airstream is increased and this increment is converted into IOP. This raises the pressure of the air stream in the central chamber, and this increment is converted into IOP<sup>29</sup>. Measured values are usually higher than with GAT<sup>30</sup>, this technique can be useful for non cooperating, bedridden patients or infants.

- Rebound tonometry (Icare)  
The rebound tonometer is a simple portable device. Although it is a contact tonometer topical anaesthetic drops are not required and the tonometer has a disposable tip to minimise the risk of cross-infection. The device processes the rebound movement of a rod probe resulting from its interaction with the eye; rebound increases (shorter duration of impact) as the IOP increases. Six measurements are taken to provide accurate measurement results. The rebound tonometer can be particularly useful in children [II,C]. The Icare ONE Home device is a variation that has been designed for self tonometry<sup>31-35</sup>.
- Tono-Pen  
The Tono-Pen is a hand-held portable tonometer that determines IOP by making contact with the cornea (central contact is recommended) through a probe tip, causing applanation/indentation of a small area. Topical anaesthetic eye drops are used. After four valid readings are obtained the averaged measurement is given together with the standard error<sup>36-38</sup>.

Both the Icare and Tono-Pen are useful for patients with corneal disease and surface irregularity as the area of contact is small [II,C].


- Transpalpebral tonometry  
This type of tonometry includes devices that measure IOP through the eyelid avoiding direct corneal contact. The Diaton<sup>®</sup> tonometer is a hand held, pen like, portable device applying this principle. The pressure-phosphene tonometer (PPT) (Proview<sup>®</sup>) has been developed as a self measurement tonometer. The threshold pressure for creating a phosphene (perception of light) associated with the localised indentation is the estimated IOP. There is insufficient evidence to replace GAT by transpalpebral tonometry<sup>39-43</sup> [I,D].
- Triggerfish<sup>®</sup> (Sensimed) has a sensor embedded in a contact lens, based on strain gauges claimed to record changes in the area of the corneo-scleral junction. There is no evidence to support the use of this device in clinical practice<sup>44</sup>.

### 1.1.2 Intraocular pressure and central corneal thickness


Central corneal thickness (CCT) influences GAT readings (Table 1.1). However, there is no agreement as to whether there is a validated and useful correction algorithm for GAT and CCT. The normal distribution of CCT is  $540 \pm 30 \mu\text{m}$  (mean  $\pm$  SD)<sup>45</sup>. CCT variations after corneal refractive surgery make difficult to interpret GAT<sup>46</sup>. A record of pre-operative CCT is helpful to manage patients undergoing refractive surgery [II,D].

**Except for unusual circumstances, there is no evidence to support the use of methods alternative to Goldmann applanation tonometry for the routine management of patients suspected of having, or that do have, glaucoma.**

## Technique of Goldmann Applanation Tonometry.



**Figure 1.1.** When there is contact between the tonometer prism (left) and the cornea, the stained tear meniscus can be observed through the prism.



**Figure 1.2.** Correct technique (A): the prism is correctly aligned to the centre of the cornea and the applied pressure is then adjusted until the inner part of the semicircles touch each other. When the reading is taken before the semicircles are aligned as in (A), the applanation pressure will not correspond correctly to the IOP shown on the dial (B). Incorrect alignment can combine with incorrect amount of fluorescein, adding error on error (C).

**Note:** In case of high or irregular astigmatism, corrections should be made. One option is to do two measurements, the first with the biprism in horizontal position and the second in vertical position and the readings should be averaged. Another way of correcting large regular astigmatism (> 3 D) is to align the red mark of the prism with the axis of the minus cylinder.

**Table 1.1** Influence of corneal status, thickness and tear film on the intraocular pressure (IOP) value measured with the Goldmann Applanation Tonometry.

Cornea Status	IOP reading erroneously high	IOP reading erroneously low
Thin central cornea		x
Thick central cornea	x	
Epithelial oedema		x
Excessive tear film		x
Insufficient tear film	x	
Corneal refractive surgery*		x

\* Corneal refractive surgeries alter tonometry reading since they modify thickness, curvature and structure of the cornea.

**Table 1.2** Differences in IOP between different tonometers and Goldmann Applanation Tonometry (GAT). Pooled estimates and summary 95% limits of agreement<sup>11-45</sup>.

Tonometer	Mean Difference between Tonometer and GAT	95% Confidence Interval		95% Limits of Agreement		% within 2 mmHg
DCT	1.8	+1.3	+2.3	-3.0	+6.6	47
NCT	0.3	-0.1	+0.7	-3.5	+4.0	69
ORA	1.5	+0.9	+2.2	-4.3	+7.3	45
Ocuton S	2.7	-1.2	+6.7	-4.0	+9.6	33
RT-(Icare)	0.9	+0.5	+1.5	-4.3	+6.3	51
TonoPen	0.2	-0.4	+0.9	-5.2	+5.7	52
Transpalpebral	-0.5	-1.3	+0.3	-7.0	+5.9	45

DCT = Dynamic Contour Tonometer; NCT = Non-Contact Tonometer; ORA = Ocular Response Analyzer; RT = Rebound Tonometer.


## 1.2 - GONIOSCOPY

Gonioscopy is an important part of the comprehensive adult eye examination and essential for evaluating patients suspected of having, or who do have glaucoma<sup>47-50</sup> [I,D] (See FC II).

The purpose of gonioscopy is to inspect the anterior chamber angle. It is based on the recognition of angle landmarks and must always include an assessment of at least the following:

- a) level of iris insertion, both true and apparent
- b) shape of the peripheral iris profile
- c) width of the angle approach, i.e.: angular separation between the corneal endothelium and the anterior surface of the peripheral iris
- d) degree of trabecular pigmentation
- e) areas of iridotrabecular apposition or synechia

### FC II - Diagnostic Gonioscopy in Open Angle in Glaucoma



\*Irido Corneal Endothelial syndrome

## 1.2.1 Anatomy

### Reference landmarks

**Schwalbe's line:** this collagen condensation of the Descemet's membrane between the trabecular meshwork and the corneal endothelium appears as a thin translucent line. Schwalbe's line may be prominent and anteriorly displaced (posterior embryotoxon), or there may be heavy pigmentation over it. A pigmented Schwalbe's line may be misinterpreted as the trabecular meshwork, particularly when the iris is convex. Indentation ('dynamic') gonioscopy and the corneal wedge method are helpful to distinguish between the structures by reliably identifying Schwalbe's line.

**Trabecular Meshwork (TM):** this extends posteriorly from Schwalbe's line to the scleral spur. Close to Schwalbe's line is the non-functional trabecular meshwork, blending into to the posterior, functional and usually pigmented TM. If the TM is not seen in 180° or more, angle closure is present. Most difficulties concerning examination of the TM relate to the determination of whether observed features are normal or pathological (particularly pigmentation), blood vessels and iris processes.

**Pigmentation:** pigment is found predominantly in the posterior meshwork. It is seen in adults, rarely before puberty and the extent can be highly variable. The most common conditions associated with dense pigmentation are: pseudexfoliation syndrome, pigment dispersion syndrome, previous trauma, previous laser treatment of the iris, uveitis and after an acute angle-closure attack.

**Blood vessels:** these are often found in normal iridocorneal angles. They characteristically have a radial or circumferential orientation, have few anastomoses and do not run across the scleral spur. They can be seen most easily in subjects with blue irides. Pathological vessels are usually thinner, have a disordered orientation and may run across the scleral spur to form a neovascular membrane. Abnormal vessels are also seen in Fuchs' heterochromic iridocyclitis and chronic anterior uveitis.

**Schlemm's canal:** is not normally visible, though it may be seen if it contains blood. Blood reflux from episcleral veins may occur in cases of carotid-cavernous fistulae, Sturge Weber syndrome, venous compression, ocular hypotony, sickle cell disease or due to suction from the goniolens.

**Scleral spur:** is of white appearance and located between the pigmented TM and the ciliary body.

**Iris processes:** are present in one third of normal eyes, more evident in younger subjects. When numerous and prominent they may represent a form of Axenfeld-Rieger syndrome/anomaly. They are distinguished from goniosynechia which are thicker and wider and may go beyond the scleral spur.

**Ciliary band and iris root:** the iris insertion is usually at the anterior face of the ciliary body, though the site is variable. The ciliary band may be wide, as in myopia, aphakia or following trauma, or narrow or not seen as in hyperopia and anterior insertion of the iris.

## 1.2.2 Techniques

Gonioscopy is an essential part of all glaucoma patients evaluation [1,D]. Gonioscopy should always be performed in a dark room, using the thinnest slit beam, taking care to avoid shining the light through the pupil because of pupil constriction in light exposure<sup>51, 52</sup> [1,D].

There are two main techniques for viewing the anterior chamber angle:

- **Direct Gonioscopy**

The use of some contact goniolenses like the Koeppe or Barkan lens permits the light from the anterior chamber to pass through the cornea so that the angle may be viewed (Fig. 1.3 top).

- **Indirect Gonioscopy**

The light from the anterior chamber is made to exit via a mirror built into a contact glass (Fig. 1.3.bottom).





Figure 1.3

**The most common Gonioscopy lenses:**


Direct	Koeppel (contact fluid required) Layden (sized for infants; contact fluid required) Worst
Indirect	Posner or Zeiss or Sussman 4 mirror (contact fluid not required) Goldmann lens, 1 to 4 mirrors (contact fluid required) CGA 1.4® Lasag (contact fluid required) Magnaview (contact fluid required)

**1.2.2.1 'Dynamic indentation' gonioscopy**

It is recommended to use a small diameter lens for indentation (e.g.: 4-mirror) [I,D]. When gentle pressure is applied by the lens on the center of the cornea, the aqueous humour is pushed back. In appositional angle-closure, the angle can be re-opened. If there is adhesion between the iris and the meshwork, as in goniosynechia, that portion of angle remains closed (Fig. 1.4(3)).

When pupillary block is the prevalent mechanism the iris becomes peripherally concave during indentation. In iris plateau configuration this iris concavity will not be extended by indentation to the extreme periphery, which is a sign of anteriorly placed ciliary processes (double hump sign). When the crystalline lens has a particularly prominent role, indentation causes the iris to move only slightly backwards, retaining a convex profile (Fig. 1.4(4)).

**To differentiate appositional from synechial closure “indentation” or “dynamic” gonioscopy is essential.**



**Figure 1.4.** Dynamic indentation gonioscopy. When no angle structure is directly visible before indentation, angle-closure may be present, and it can be synechial or appositional (1). If during indentation the iris moves peripherally backwards and the angle recess widens (2), the picture in (1) is to be interpreted as appositional closure and a suspicion of relative pupillary block is raised (2). When during indentation the angle widens but iris strands remain attached to the angle outer wall (3), the picture in (1) is to be interpreted as synechial closure. A large and/or anteriorly displaced lens causes the iris to move only slightly and evenly backwards during indentation (4) making the lens a likely component of angle-closure.

### 1.2.2.2 Gonioscopy technique without indentation

With indirect Goldmann-type lenses it is preferable to start by viewing the inferior angle, which often appears wider than the superior angle, because it is easier to identify the different structures. Then to continue rotating the mirror [II,D]. The anterior surface of the lens should be kept perpendicular to the observation axis so that the appearance of the angle structure is not changed as the examination proceeds. The four quadrants are examined by a combination of slit-lamp movements and prism rotation.

In case of a narrow approach, it is possible to improve the visualization of the angle recess by asking the patient to look in the direction of the mirror being used.

### Practical points

- **Related to the technique**

Gonioscopy should be performed in a dark room and with a small slit beam [I,D]. The most widely used technique is indirect gonioscopy where the angle is viewed in a mirror of the lens. The position of the globe is of importance. Angle width grading must be performed with the eye in primary position to avoid misclassification. If the patient looks in the direction of the mirror the angle appears wider and vice versa. A second pitfall is inadvertent pressure over the cornea, which will push back the iris, and gives an erroneously wide appearance to the angle. This occurs when the diameter of the lens is smaller than the corneal diameter e.g.: 4-mirror lenses. With a large diameter goniolens, indentation is transmitted to the periphery of the cornea distorting the angle.

- **Related to the anatomy**

Recognition of angle structures may be impaired by variations in the anterior segment structures like poor pigmentation, iris convexity or existence of pathological structures.

### Pharmacological mydriasis

Dilation of the pupil with topical or systemic drugs can trigger angle-closure. Angle-closure attacks can occur, even bilaterally, in patients treated with systemic parasympatholytics before, during or after abdominal surgery and has been reported with many systemic drugs such as serotonergic ‘appetite’ suppressants<sup>53</sup>.

Although pharmacological mydriasis with topical tropicamide and neosynephrine is safe in the general population even in eyes with a narrow approach, IOP elevation can occur in occasional patients (approx. 10%)<sup>54</sup>. Screening with van Herick’s test can detect angles at risk prior to dilating (Fig. 1.6).

### Systemic drugs with effects on the angle


Theoretically, although any psychoactive drugs have the potential to cause angle-closure, it is unlikely that pre-treatment gonioscopy findings alone are of help to rule out such risk. In eyes with narrow angles, it makes sense to repeat gonioscopy and tonometry after initiation of treatment [II,D]. Prophylactic laser iridotomy needs to be evaluated against the risks of angle-closure or of withdrawal of the systemic treatment [II,D]. (See Ch. 2.4). None of these drugs is contraindicated per se in open-angle glaucoma. Ciliochoroidal detachment with bilateral angle-closure has been reported after oral sulpha drugs and topiramate<sup>55</sup>.

## 1.2.3 Grading

The use of a grading system for gonioscopy is highly desirable<sup>48, 56, 57</sup> [I,D]. It stimulates the observer to use a systematic approach in evaluating angle anatomy, it allows comparison of findings at different times in the same patients, or to classify different patients.

The Spaeth gonioscopy grading system is the most detailed (Fig. 1.5)<sup>48</sup>.

Other practical grading systems are those of Shaffer<sup>58</sup> and Kanski<sup>59</sup>; both are based on angle width and visibility of the structures.



**Figure 1.5.** The Spaeth Grading System of gonioscopy finding.




Figure 1.6. The Van Herick test.

### 1.2.3.1 Slit lamp-grading of peripheral AC depth - The Van Herick Method

The Van Herick grading is an important part of any comprehensive eye examination (Fig. 1.6) [II,D]. This method is very useful if a gonioscope is not available<sup>57, 60</sup> [I,D] and can identify the need for gonioscopy in patients not otherwise suspected of glaucoma but it is not a substitute for gonioscopy. This technique is based on the use of corneal thickness as a unit measure of the depth of the anterior chamber at the furthest periphery, preferably on the temporal side.

Grade 0 represents iridocorneal contact.

A space between iris and corneal endothelium of  $< 1/4$  corneal thickness, is a Shaffer grade I. When the space is  $\geq 1/4 < 1/2$  corneal thickness the grade is II. A grade III is considered not occludable, with an irido/endothelium I distance  $\geq 1/2$  corneal thickness.

### 1.2.4 Anterior Segment Imaging Techniques

UBM, anterior segment OCT and Scheimpflug cameras can be useful in some circumstances. Added to gonioscopy, these techniques help elucidate the mechanism of angle-closure in many cases [II,D]. Due to their limited availability and costs however, they are applied to cases which are most difficult to interpret<sup>61-69</sup>. UBM is very helpful in diagnosis behind the iris and the pigmented epithelium (tumours, cysts). Anterior segment OCT and Scheimpflug cameras are suitable for volumetric measurements and documentation of the dynamics of the chamber angle at different light conditions. These instruments currently give information only on the examined sector and not about the total circumference. None of these imaging methods provides sufficient information about the anterior chamber angle anatomy to be considered a substitute for gonioscopy<sup>70-89</sup>

### 1.3 - OPTIC NERVE HEAD AND RETINAL NERVE FIBRE LAYER

Glaucoma changes the appearance of the optic nerve head (ONH) and the retinal nerve fibre layer (RNFL) in a characteristic fashion.

Contour changes can best be appreciated with a magnified stereoscopic view. Therefore the initial examination, and follow-up examinations for contour change, should be made preferably through a dilated pupil [I,D]. Interim examinations, aimed at detecting striking features such as disc haemorrhages, may be performed through an undilated pupil stereoscopic examination of the posterior pole is best performed with a:

- Indirect non-contact fundus lens with sufficient magnification at the slit-lamp or
- Direct contact fundus lens at the slit-lamp

The direct ophthalmoscope is also useful for ONH and RNFL examination. Although three-dimensional information using parallax movements is possible, binocular examination through a dilated pupil is superior. The clinical evaluation of the ONH and RNFL should assess the following features [I,D].

#### 1.3.1 Clinical Examination - Qualitative


##### 1.3.1.1 Neuroretinal Rim

In a healthy eye, the shape of the rim is influenced by size, shape and tilting of the optic nerve head. The disc is usually slightly vertically oval, often more so in black subjects who may also have larger discs. In normal sized discs, the neuroretinal rim is typically at least as wide at the 12 and 6 o'clock positions as elsewhere and usually widest (83% of eyes) in the infero-temporal sector, followed by the supero-temporal, nasal and then temporal sectors (the 'ISNT' rule, see fig. 1.10)<sup>90</sup>.

This pattern is less obvious in larger discs, in which the rim is distributed more evenly and in a smaller discs where cupping may not be evident. Larger and a smaller discs are harder to interpret: e.g., in small discs the changes associated with glaucoma may not result in cupping, but 'saucerization' of the disc surface instead, and in large optic discs the normal rim is relatively narrow and can potentially be misinterpreted as glaucomatous.

The exit of the optic nerve from the eye may be oblique, giving rise to a tilted disc. Tilted discs are more common in myopic eyes, and show a wider, gently sloping rim in one disc sector and a narrower, more sharply-defined rim in the opposite sector. Discs in highly myopic eyes are even harder to interpret.

Glaucoma is characterized by progressive narrowing of the neuroretinal rim. The pattern of rim loss varies and may take the form of diffuse narrowing, localized notching, or both in combination (Fig. 1.7). Narrowing of the rim, while occurring in all disc sectors, is generally more common and greatest at the inferior and superior poles<sup>91-95</sup>



**Figure 1.7.** Progression of glaucomatous damage at the optic disc:  
 Early localized loss (A1), advancing to localized plus diffuse rim loss (A2).  
 Early localized rim loss, polar notches (B1); more advanced polar notches (B2).  
 Diffuse or concentric rim loss, early (C1); advanced (C2).  
 Diffuse rim loss (D1), followed by localized rim loss (notch) (D2).

© European Glaucoma Society

### 1.3.1.2 Retinal nerve fibre layer


The RNFL appearance is best assessed with a red-free (green) photograph. Clinically, the RNFL can be assessed with the red-free light or a short, narrow beam of bright white light at high magnification to explore the parapapillary region. In healthy eyes, smaller retinal vessels are embedded in the RNFL. The RNFL surface is best seen if the focus is adjusted just anterior to the retinal vessels.

The fibre bundles are seen as silver striations. About two disc diameters from the disc the RNFL thins and feathers out. Slit-like, groove-like, or spindle-shaped apparent defects, narrower than the retinal vessels, may be seen in the normal fundus. The RNFL becomes less visible with age, and is more difficult to see in less pigmented fundi.

Defects are best seen within two disc diameters of the disc. Focal (wedge and slit) defects are seen as dark bands, wider than retinal vessels and extending from the disc margin, unless obscured by vessels. These focal defects are more easily seen than generalized thinning of the RNFL, which manifests as a loss of brightness and density of striations. When the RNFL is thinned, the blood vessel walls are sharp and the vessels appear to stand out in relief against a matt background. The initial abnormality in glaucoma may be either diffuse thinning or localized defects. Since the prevalence of RNFL defects is < 3% in the normal population, their presence is likely to be pathological<sup>96-98</sup>.

### 1.3.1.3 Optic disc haemorrhages

The prevalence of small ('splinter') haemorrhages on or bordering the optic disc has been estimated to be  $\leq 0.2\%$  in the normal population<sup>99</sup>. On the other hand, a large proportion of glaucoma patients have optic disc haemorrhages (ODHs) at one time or another (Fig. 1.8). They are very often overlooked at clinical examinations, and are easier to find in photographs<sup>100-103</sup>. Many studies have shown that ODHs are associated with disease progression.



**Figure 1.8.** Optic disc haemorrhage.


### 1.3.1.4 Vessels at the optic disc

Narrowing of the neuroretinal tissue will change the position of the vessels at the optic disc with bending, bayoneting or barring of circumlinear vessels. Those positional changes are particularly important to observe when looking for progression, in comparison to a baseline photo.

### 1.3.1.5 Parapapillary atrophy

Parapapillary atrophy can be differentiated into an Alpha zone, which is present in almost any eye, and into a Beta zone, which is present in approximately 25% of normal eyes and in a significantly higher percentage of eyes with glaucoma<sup>104-106</sup>.

The Alpha zone has been defined as irregular hyperpigmentation and hypopigmentation and it is located in the periphery of parapapillary atrophy. The Beta zone is characterized by visible sclera and visible large choroidal vessels and a location between the peripapillary ring and Alpha zone. Both zones are usually located at the temporal margin of the optic disc, more often in the inferotemporal region than in the superotemporal region. Histologically, the Alpha zone corresponds to irregularities in the retinal pigment epithelium, and the Beta zone shows a complete loss of retinal pigment epithelium, an almost complete loss of photoreceptors and a closure of the choriocapillaris. The Beta zone may be associated with a greater amount of glaucomatous optic neuropathy and a higher risk of further progression of glaucoma<sup>107</sup>. The location of the Beta zone outside the optic disc spatially correlates with the location of the most marked loss of neuroretinal rim inside of the optic disc, together with the longest distance to the central retinal vessel trunk in the optic nerve head<sup>104</sup>. In clinical routine, a large ophthalmoscopic Beta zone (in particular in non-myopic eyes) should be regarded as an extra clue, and not as a definite sign of glaucoma (Fig. 1.9) [I,C].



**Figure 1.9.** ONH with parapapillary atrophy. The Alpha zone is located peripheral to beta zone, and is characterized by irregular hypo- and hyperpigmentation. The Beta zone of atrophy is adjacent to the optic disc edge, external to Elschnig's ring (a white circular band that separates the intra- from the peri-papillary area of the optic disc), with visible sclera and large choroidal vessels.

© European Glaucoma Society

### 1.3.1.6 The ISNT rule

In normal eyes with a normal optic disc shape, with a greater vertical diameter, the neuroretinal rim shows a characteristic shape: it is usually widest at the inferior disc pole, followed by the superior disc pole, the nasal disc region, and finally the temporal disc region<sup>108</sup>. For mnemonic reasons, this sequence of disc sectors was abbreviated as “ISNT” (Inferior-Superior-Nasal-Temporal) rule. In many eyes, the rim can be wider superiorly than inferiorly, however in almost all normal eyes the rim is smallest in the temporal 60° of the optic nerve head (Fig. 1.10). The most important letter in the “ISNT”-rule is therefore the “T”. The application of the ISNT rule is helpful for detecting early glaucomatous optic nerve damage, since in the early stage of glaucoma, the rim gets smaller preferentially in temporal inferior disc region or the temporal superior disc region, leading to a rim shape in which the rim can be equal in width in the inferior or superior region as compared with the temporal region. For the assessment of the ISNT rule, it is important to consider that the area of the peripapillary ring does not belong to the neuroretinal rim. It holds true in particular for the temporal disc region.





Figure 1.10. The ISNT rule.

### 1.3.2 Clinical Examination - Quantitative

#### 1.3.2.1 Optic disc size (vertical disc diameter)

The optic disc size greatly varies in the population. The width of the rim and, conversely, the size of the cup, vary with the overall size of the disc. The mean vertical disc diameter is approximately 1.5 mm<sup>109</sup>.

The vertical diameter of the optic disc can be measured at the slit lamp using a handheld high power convex lens. The slit beam should be coaxial with the observation axis; a narrow beam is used to measure the vertical disc diameter using the inner margin of the white Elschnig's ring as the reference. A correction factor needs to be used depending on the magnification of the handheld lens (Fig. 1.11).




Measured vertical diameter of optic disc			
	Small	Medium	Large
Disc area	<1.6 mm <sup>2</sup>	1.6 to 2.8 mm <sup>2</sup>	>2.8 mm <sup>2</sup>
Volk 60 D	<1.65 mm	1.65 to 2.2 mm	>2.2 mm
78 D	<1.3 mm	1.3 to 1.75 mm	>1.75 mm
90 D	<1.1 mm	1.1 to 1.45 mm	>1.45 mm
Superfield	<1.15 mm	1.15 to 1.50 mm	>1.5 mm
Digital 1.0x	<1.5 mm	1.5 to 1.95 mm	>1.95 mm
Super 66	<1.45 mm	1.45 to 1.9 mm	>1.9 mm
Nikon 60 D	<1.45 mm	1.45 to 1.9 mm	>1.9 mm
90 D	<0.95 mm	0.95 to 1.25 mm	>1.25 mm
Haag-Streit Goldmann	<1.3 mm	1.3 to 1.7 mm	>1.7 mm

Figure 1.11. Optic disc size assessed at the slit lamp with handheld high power convex lens.

### 1.3.2.2 Rim Width and Cup/Disc ratio

A large Cup/Disc Ratio (CDR) has been used as a sign of glaucoma damage. However, the CDR depends on the disc size, and a large CDR in normal large discs may be erroneously considered glaucomatous and a small CDR in glaucomatous small discs may be erroneously considered as normal<sup>110</sup> (Fig. 1.12). The use of CDR to classify patients is not recommended and the attention should be focused on the disc rim [I,D].

In healthy eyes, cupping tends to be symmetrical between the two eyes, the vertical CDR difference being less than 0.2 in over 96% of normal subjects. A difference in CDR between eyes with equal optic disc size is suggestive of acquired damage and glaucoma



**Figure 1.12.** Optic nerve heads with different disc areas but with the same rim area and the same number of retinal nerve fibres: small size disc (disc area less than 2 mm<sup>2</sup> and C/D=0.3), mid-size disc (disc area between 2 and 3 mm<sup>2</sup>, C/D=0.5) and large disc (disc area greater than 3 mm<sup>2</sup> and C/D=0.8).

### 1.3.3 Recording of the Optic Nerve Head (ONH) Features

At baseline, some form of imaging is recommended to provide a record of the ONH appearance [I,D]. If colour photos are not available, a detailed manual drawing is recommended. Even if it is difficult to draw a good picture of the ONH, the act of making a drawing encourages a thorough clinical evaluation of ONH [II,D].

Stereoscopic is preferred to non-stereoscopic photography [I,D]. Colour photography with a 15° field gives optimal magnification. Sequential photographs can be used to detect progression of optic disc damage.

#### 1.3.3.1 Quantitative Imaging

Quantitative imaging of the optic nerve head, retinal nerve fibre layer and inner macular layers have been widely used to assist glaucoma diagnosis and to detect glaucomatous progression during follow-up.

#### 1.3.3.2 Classification

For cross sectional classification, imaging instruments typically provide three potential outcomes: “within normal limits”, “borderline” and “outside normal limits”. No imaging device provides a clinical diagnosis but just a statistical result, based on comparison of the measured parameters with the corresponding normative database of healthy eyes. Therefore an interpretation of the result in the context of all clinical data is mandatory [I,D]. The clinician should also assess the quality of the image and analysis and judge whether the normative database is relevant for the particular patient before including the classification in the assessment of the patient [I,D]. For instance, imaging artefacts and software errors are quite common and more frequent in eyes that are highly myopic or have very tilted nerves, and few devices have normative data appropriate to these eyes. The various imaging technologies have their own advantages and limitations, and their classification shows only partial agreement in early glaucoma<sup>111</sup>. In addition, agreement between classification with quantitative imaging and visual field testing is only moderate in early glaucoma.

#### 1.3.3.3 Detection of progression

Most commercial imaging devices have software for quantifying glaucomatous progression, including the rate of progression. The classification algorithms described above should not be used to assess progression [I,D]. In general, normative databases are not needed for progression analysis because the patient's baseline images provide the reference for change. High quality baseline images are, therefore, of considerable importance. The user should assess the test series for the quality of images and software analysis before including the software output in the assessment of the patient [I,D]. Agreement between structural progression and functional deterioration, over the relatively short duration of reported studies, is only partial or poor<sup>112, 113</sup>.

Provided the images in a series are of good quality and progression analysis is

consistent over several tests, imaging devices provide useful data, additional to those gained from visual field testing, concerning a patient's glaucoma damage.

#### 1.3.3.4 Imaging instruments

A complete list of all available technologies is beyond the scope of the guidelines.

- Heidelberg Retina Tomography (HRT)**  
 The Heidelberg Retina Tomograph (Heidelberg Engineering, Heidelberg, Germany) is used to profile and measure the three-dimensional anatomy of the optic nerve head and surrounding tissues. It can also detect progressive changes in optic nerve head surface topography. To classify an optic nerve head, three methods can be used: the Moorfields Regression Analysis (MRA), the linear discriminant analysis formulas and the Glaucoma Probability Score (GPS)<sup>114-116</sup>. The classification algorithms tend to over-report 'outside normal limits' in large optic discs. For progression analysis, the software provides a map of surface height changes compared to baseline (Topographic Change Analysis [TCA]); the area and volume of changing regions is presented as a plot over time. Graphs of rim area over time are also available.
- Scanning laser polarimetry (GDx-ECC)**  
 The GDx-ECC instrument (Carl Zeiss Meditech Inc., Dublin, CA, USA) measures retinal nerve fibre layer thickness around the optic nerve head on the basis of retardation of the illuminating laser light. All polarizing structures in the eye cause retardation, especially the cornea. With Enhanced Corneal Compensation (ECC), polarization artefacts arising both from the anterior segment and behind the retina are attenuated<sup>117</sup>. The main parameter to help distinguish healthy subjects from glaucomatous patients is the NFI (nerve fibre indicator), although clinicians should also evaluate the distribution of the retinal nerve fibre layer around the optic disc (the 'TNSIT' curve). Trend and change from baseline analyses for progression are available.
- Optical coherence tomography (OCT)**  
 Optical coherence tomography is based on interferometry. Current instruments, Fourier-domain (FD) or Spectral domain (SD) and swept-source OCT systems, provide faster image acquisition, higher resolution and better image segmentation than time-domain OCT. Several companies produce FD/SD OCT instruments. Their technical, software and normative database characteristics vary; thus the values measured with different OCT systems are not interchangeable. Three main parameter groups are measured and analysed for classification and detection of progression: Optic Nerve Head, Retinal Nerve Fibre Layer and Ganglion Cell Complex. In general, the optic nerve head parameters with OCT may be less informative than the retinal nerve fibre layer and the ganglion cell complex parameters<sup>118</sup>. To identify and measure glaucomatous progression with OCT systems trend analysis of the retinal nerve fibre layer thickness and inner macular retinal thickness parameters are particularly useful<sup>119</sup>.

**How to use imaging at baseline [II,D]**

Glaucoma suspects with normal or unreliable visual field

Glaucoma with early and moderate damage

**How to use imaging for monitoring progression [II,D]**

Frequency should be similar to that for VF testing

- Patients should be followed with the same test/method to facilitate estimation of progression [I,D].
- Baseline, repeated within 3 months after baseline, and then up to 4 more times in the first two years in case of high risk of progression [II,D].
- Baseline, repeated annually, for ocular hypertensives [II,D].

Although knowing the test-retest variability would be indispensable in determining the optimal frequency of performing imaging tests, in every-day clinical work it seems currently impossible to take into account the large number of parameters and their largely variable reproducibility nor to verify the cost effectiveness of imaging for glaucoma<sup>120</sup>.

## 1.4 - PERIMETRY

### 1.4.1 Perimetry Techniques

Visual field testing is important for the diagnosis of glaucoma, and even more important for follow-up and management of glaucoma [I,D].

A complete list of all available technologies and strategies is beyond the scope of the guidelines.

#### 1.4.1.1 Computerised and manual perimetry

Static computerised perimetry should be preferred in glaucoma management. Kinetic e.g. Goldmann perimetry is not suitable for detection of early glaucomatous field loss and small defects will often be lost between isopters<sup>121</sup>.

Computerised perimetry is also less subjective; the results are numerical and tools for computer-assisted interpretation are available. Manual kinetic perimetry may be helpful in patients who are unable to perform automated perimetry.

#### 1.4.1.2 Standard Automated Perimetry - SAP

Glaucoma perimetry has become more standardised over time and today the term Standard Automated perimetry (SAP) is often used. SAP refers to static computerised threshold perimetry of the central visual field performed with white stimuli on a dimmer white background.

- Test algorithms and programs

In glaucoma care threshold perimetry is the recommended standard [I,D]. Commonly used threshold algorithms are: 'SITA Standard' and 'SITA Fast' in the Humphrey perimeter. SITA Fast has the advantage of reduced test time but this may come at the cost of increased variability. In the Octopus perimeter the commonly used threshold algorithms called the 'Dynamic Strategy'. TOP algorithm is more rapid, but may have lower resolution than other threshold tests because threshold values are determined by averaging test results from several adjacent test point locations<sup>122</sup>.

Glaucoma perimetry is performed using a Goldmann size III stimulus in the central 25–30° field where the great majority of retinal ganglion cells are located [I,D].

Common test point patterns are the identical 30-2 and 32 test point patterns of the Humphrey and Octopus perimeters respectively and G1 and G2 patterns of the Octopus, which cover the central 30°. A commonly used pattern is the 24-2 pattern of the Humphrey perimeter, which covers a somewhat smaller area and thereby reduces test time. Only a small amount of information is lost if the smaller patterns are used as compared to the larger ones, and common test artefacts from, e.g., trial lens rims or droopy lids are less common with the more central patterns.

- Selecting a test

It is recommended that clinicians select and familiarise themselves with suitable SAP tests. Patients should be followed with the same test to facilitate estimation of

## Patient Examination


progression [I,D]. For those with very advanced disease it may be necessary to consider using a Goldmann size V stimulus rather than size III, or a perimetric strategy which focuses more closely on the remaining area of visual field. In both perimeters one may use test point patterns covering only the central 10° of the field in eyes which have only ‘tunnel’ fields left, e.g. the Octopus M1 or M2 or the Humphrey 10-2 [I,D].

The Humphrey Field Analyzer and the Octopus perimeter are the two most commonly used SAP perimeters in Europe. Other less frequently used SAP perimeters also having threshold programmes are available.

### 1.4.1.3 Non-conventional perimetry

Other modalities of computerised perimetry use different stimuli to SAP. Examples are SWAP (Short Wavelength Automated Perimetry), FDT (Frequency Doubling Technology), HEP (Heidelberg Edge Perimetry) and HRP (High-pass resolution perimetry or ring perimetry) and flicker perimetry. There is insufficient evidence that these tests offer any advantage over SAP<sup>123-126</sup>.

## FC III - Initial Visual Field Evaluation



Consider the reliability of the test before making decisions based on it

#### 1.4.1.4 Patient instructions

The role of the operator is of great importance. To patients who are naive to the test, the operator must explain what to expect and how to react to stimuli. The operator needs to be in the vicinity of the perimeter to react to any patient queries [I,D]. A quiet, dimly lit environment should be ensured. A short demonstration, before the actual test starts, will also help patients understand the test. The operator should have taken the tests to better understand the experience of taking the test. It should be explained that most stimuli will be very dim and even patients with normal visual fields will be expected to 'miss' many stimuli [II,D].

### 1.4.2 Interpreting test results

#### 1.4.2.1 Printouts

Humphrey and Octopus both provide similar statistical analyses of single field test results presented on printouts containing maps of the visual field plus visual field indices and other means of interpreting a test result.

- The numerical threshold map provides the 'raw' estimated threshold values at each test point location.
- The grey scale or colour coded map provides a graphical representation of the numerical threshold map.
- The numerical total deviation map shows point-wise differences between the age-corrected normal threshold value at each test point location and the measured value.
- The numerical pattern deviation map shows the same values but after correction for diffuse loss of sensitivity. Thus, it highlights focal loss of sensitivity.
- Probability maps provide the statistical significance of the numerical deviations.

#### 1.4.2.2 Reliability indices

These indices are meant to estimate patient reliability. With proper instructions almost all patients are able to perform reliable tests.

High frequencies of false positive answers (FP), are clearly a sign of poor reliability, but high frequencies of false negatives (FN) are of relatively little value. High rates of fixation losses (FL) may indicate poor attention to the fixation target. In most modern perimeters patients' fixation is continuously monitored during the test by an automatic eye/gaze tracker.

The operator has an important role in monitoring and assessing the reliability of the test as it is performed and informing the clinician e.g. by annotating the test result if necessary.

### 1.4.2.3 Visual field indices

Visual field indices are numbers summarising perimetric test results. An useful index is MD (mean defect in the Octopus system or mean deviation in the Humphrey system). MD represents the average difference between normal age-corrected sensitivity values and the measured threshold values at all test point locations. A new index developed for the Humphrey perimeter is VFI, which is similar to the MD value but more centrally weighted, expressed in percent rather than in decibels and more resistant to diffuse loss<sup>127, 128</sup>.

The global indices include PSD (Humphrey) and LV (Octopus) measure the local spatial variability of the visual field. PSD and LV can be used for diagnosis, but they are less informative than the probability maps. Software to produce graphs mapping visual field loss to expected anatomical regions is available.

### 1.4.2.4 Recording the visual field indices

A simple method to record serial data from VF is the GSS; this will give a visual overview, without any statistical support<sup>129, 130</sup>

### 1.4.2.5 Summarising diagnostic features

- The Glaucoma Hemifield Test (GHT)  
The Glaucoma Hemifield Test is incorporated in the Humphrey perimeter. This analysis classifies results as 'within normal limits', 'outside normal limits' or 'borderline'. The classification of outside normal limits is designed to identify glaucoma. Two more GHT classifications are 'general depression of sensitivity' and 'abnormally high sensitivity which goes hand in hand with high frequencies of FP responses'.
- The Bebié curve  
The Bebié curve or the cumulative defect curve in the Octopus system is a summary graph of localised and diffuse sensitivity loss. In entirely diffuse loss the curve of the measured sensitivities is lower than but parallel to the displayed normal curve. In focal loss the right part of the measured curve is depressed as compared to the normal reference curve.
- Diagnosis based on clustered points  
Clustered test point locations with significantly reduced sensitivity are more reliable indicators of early glaucomatous field loss than scattered points. A rule, which is often used to classify a test result as glaucomatous, stipulates a minimum of three clustered points with significantly depressed sensitivity, of which one should have a significance of  $p < 1\%$  [I,D]. Usually, the test point locations immediately surrounding the blind spot are ignored in this analysis.


1.4.2.6 Confirmation of classification

Field defects which appear clearly glaucomatous and fit with the clinical picture may not need confirmation to support a diagnosis [I,D]. Visual fields with subtle defects may require confirmatory tests. (See FC IV).

**The learning effect.**

Many subjects show an improvement in performance reflected as improved reliability and sensitivity over the first few tests.

**FC IV - Diagnostic strategy when initial visual field is abnormal**



### 1.4.2.7 Assessing progression

In follow-up it is important to know whether the visual field of an eye is deteriorating and the rate of progression [I,D]. When assessing change from baseline, apparent progression needs to be confirmed in two or more tests [I,D].

There are two main approaches to computer-assisted progression analyses:

1. Event analyses (designed to answer the question of whether the field has progressed)  
With Glaucoma Change Probability Maps (GCPMs) all visual field tests are compared to baseline consisting of an average of two baseline tests. Test point locations that have deteriorated more than the expected test-retest variation are flagged. Eyes that show deterioration of at least three test point locations are flagged as possibly progressing if the finding is repeated in two consecutive tests and likely progressing if existing in three consecutive tests. The rules used in EMGT<sup>131</sup> are part of the HVF Analyser's guided progression analyses (GPA) program.
2. Trend analyses (quantify the rate of progression)  
The perimetric rate of progression is the velocity of worsening of the visual field, and is usually measured by performing linear regression analysis of the MD index or the newer VFI index over time. With MD rate of progression is expressed in dB/year, and with VFI in %/year.  
Trend analysis of global indices includes linear regression of MD and VFI for the Humphrey and linear regression of MD, LV, DD and LD for the Octopus. The Octopus provides trend analysis of functionally related clusters of test points. Several stand-alone software programs are available to perform trend analysis of individual test locations, clusters or global indices, depending on the product. These include Peridata, PROGRESSOR and Eye Suite. Some of the systems described above use trend data to try to predict the future status of the visual field.

### 1.4.2.8 Number of tests

Commonly used event and trend analyses require at least five and preferably more tests to detect progression. However in some cases progression may be detected before this. This demonstrates the need for relatively frequent perimetry in those eyes where it is considered necessary to find early progression.

Determining the rate of progression of an individual eye requires a long enough time span (at least two years) and enough field tests. It is important to identify eyes showing a fast rate of progression at an early stage. Ideally, all newly diagnosed glaucoma patients should be tested with SAP three times per year during the first two years after diagnosis [II,D].

### 1.4.3 Staging of Visual Field Defects

When discussing disease stages in glaucoma, the status of the visual field is often used as the most important reference. A discrete-levels staging system<sup>132</sup>, modified from the Hodapp-Parrish classification<sup>133</sup> has been in use for several years.

The GSS use a combination of MD and PSD to chart the stage of damage<sup>129, 130</sup>.

Staging systems may be of great interest in scientific studies, cost studies *et cetera*, but they are of limited value in clinical management.

Ideally for glaucoma management one should be able to detect and quantify disease progression in small steps rather than identifying only the transition from one stage to the next [I,D].

#### The Hodapp Classification

##### EARLY GLAUCOMATOUS LOSS

- a) MD < -6 dB
- b) Fewer than 18 points depressed below the 5% probability level and fewer than 10 points below the p < 1% level
- c) No point in the central 5 degrees with a sensitivity of less than 15 dB

##### MODERATE GLAUCOMATOUS LOSS

- a) MD < -12 dB
- b) Fewer than 37 points depressed below the 5% probability level and fewer than 20 points below the p < 1% level
- c) No absolute deficit (0 dB) in the 5 central degrees
- d) Only one hemifield with sensitivity of < 15 dB in the 5 central degrees

##### ADVANCED GLAUCOMATOUS LOSS

- a) MD > -12 dB
- b) More than 37 points depressed below the 5% probability level or more than 20 points below the p < 1% level
- c) Absolute deficit (0 dB) in the 5 central degrees
- d) Sensitivity < 15 dB in the 5 central degrees in both hemifields

## References:

1. Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. *Health Technol Assess* 2007;11(41):iii-iv, ix-x, 1-190.
2. Leydecker WA, K.; Neumann, H.G. The intraocular pressure of healthy eyes. *Klin Mbl Augenheilk* 1958(133):662-70.
3. Armaly MF. On the Distribution of Applanation Pressure. I. Statistical Features and the Effect of Age, Sex, and Family History of Glaucoma. *Arch Ophthalmol* 1965;73:11-8.
4. Davanger M, Ringvold A, Blika S, Elsas T. Frequency distribution of IOP. Analysis of a material using the gamma distribution. *Acta Ophthalmol (Copenh)* 1991;69(5):561-4.
5. Hollows FC, Graham PA. Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. *Br J Ophthalmol* 1966;50(10):570-86.
6. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. *Surv Ophthalmol* 1980;24(Suppl):335-610.
7. Klein BE, Klein R, Linton KL. Intraocular pressure in an American community. The Beaver Dam Eye Study. *Invest Ophthalmol Vis Sci* 1992;33(7):2224-8.
8. Bonomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna-Neumarkt Study. *Ophthalmology* 1998;105(2):209-15.
9. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. *Ophthalmology* 1996;103(10):1661-9.
10. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. *Arch Ophthalmol* 1991;109(8):1090-5.
11. Goldmann H. Un nouveau tonometre d'applanation. *Bull Soc Ophthalmol Fr* 1955(67):474-8.
12. Cook JA, Botello AP, Elders A, et al. Systematic review of the agreement of tonometers with Goldmann applanation tonometry. *Ophthalmology* 2012;119(8):1552-7.
13. Kaufmann C, Bachmann LM, Thiel MA. Comparison of dynamic contour tonometry with goldmann applanation tonometry. *Invest Ophthalmol Vis Sci* 2004;45(9):3118-21.
14. Doyle A, Lachkar Y. Comparison of dynamic contour tonometry with Goldmann applanation tonometry over a wide range of central corneal thickness. *J Glaucoma* 2005;14(4):288-92.
15. Barleon L, Hoffmann EM, Berres M, et al. Comparison of dynamic contour tonometry and Goldmann applanation tonometry in glaucoma patients and healthy subjects. *Am J Ophthalmol* 2006;142(4):583-90.
16. Martinez-de-la-Casa JM, Garcia-Feijoo J, Vico E, et al. Effect of corneal thickness on dynamic contour, rebound, and Goldmann tonometry. *Ophthalmology* 2006;113(12):2156-62.
17. Halkiadakis I, Patsea E, Chatzimichali K, et al. Comparison of dynamic contour tonometry with Goldmann applanation tonometry in glaucoma practice. *Acta Ophthalmol* 2009;87(3):323-8.
18. Fogagnolo P, Figus M, Frezzotti P, et al. Test-retest variability of intraocular pressure and ocular pulse amplitude for dynamic contour tonometry: a multicentre study. *Br J Ophthalmol* 2010;94(4):419-23.

19. Tonnu PA, Ho T, Sharma K, et al. A comparison of four methods of tonometry: method agreement and interobserver variability. *Br J Ophthalmol* 2005;89(7):847-50.
20. Yaoeda K, Shirakashi M, Fukushima A, et al. Measurement of intraocular pressure using the NT-4000: a new non-contact tonometer equipped with pulse synchronous measurement function. *J Glaucoma* 2005;14(3):201-5.
21. Kotecha A, Elsheikh A, Roberts CR, et al. Corneal thickness- and age-related biomechanical properties of the cornea measured with the ocular response analyzer. *Invest Ophthalmol Vis Sci* 2006;47(12):5337-47.
22. Medeiros FA, Weinreb RN. Evaluation of the influence of corneal biomechanical properties on intraocular pressure measurements using the ocular response analyzer. *J Glaucoma* 2006;15(5):364-70.
23. Kotecha A, White E, Schlottmann PG, Garway-Heath DF. Intraocular pressure measurement precision with the Goldmann applanation, dynamic contour, and ocular response analyzer tonometers. *Ophthalmology* 2010;117(4):730-7.
24. Sullivan-Mee M, Gerhardt G, Halverson KD, Qualls C. Repeatability and reproducibility for intraocular pressure measurement by dynamic contour, ocular response analyzer, and Goldmann applanation tonometry. *J Glaucoma* 2009;18(9):666-73.
25. Vandewalle E, Vandenbroeck S, Stalmans I, Zeyen T. Comparison of ICare, dynamic contour tonometer, and ocular response analyzer with Goldmann applanation tonometer in patients with glaucoma. *Eur J Ophthalmol* 2009;19(5):783-9.
26. Sacu S, Vass C, Schemper M, Rainer G. Self-tonometry with the Ocuton S: evaluation of accuracy in glaucoma patients. *Acta Ophthalmol Scand* 2004;82(4):405-9.
27. Marchini G, Babighian S, Specchia L, Perfetti S. Evaluation of the new Ocuton S tonometer. *Acta Ophthalmol Scand* 2002;80(2):167-71.
28. Langham ME, McCarthy E. A rapid pneumatic applanation tonometer. Comparative findings and evaluation. *Arch Ophthalmol* 1968;79(4):389-99.
29. Morrison JC, Pollack IP. *Glaucoma: science and practice*. New York: Thieme Medical Publishing, 2003; 544.
30. Quigley HA, Langham ME. Comparative intraocular pressure measurements with the pneumatonograph and Goldmann tonometer. *Am J Ophthalmol* 1975;80(2):266-73.
31. Nakamura M, Darhad U, Tatsumi Y, et al. Agreement of rebound tonometer in measuring intraocular pressure with three types of applanation tonometers. *Am J Ophthalmol* 2006;142(2):332-4.
32. Brusini P, Salvetat ML, Zepieri M, et al. Comparison of ICare tonometer with Goldmann applanation tonometer in glaucoma patients. *J Glaucoma* 2006;15(3):213-7.
33. Ruokonen PC, Schwentek T, Draeger J. Evaluation of the impedance tonometers TGDc-01 and iCare according to the international ocular tonometer standards ISO 8612. *Graefes Arch Clin Exp Ophthalmol* 2007;245(9):1259-65.
34. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, Garcia-Sanchez J. Reproducibility and clinical evaluation of rebound tonometry. *Invest Ophthalmol Vis Sci* 2005;46(12):4578-80.
35. Johannesson G, Hallberg P, Eklund A, Linden C. Pascal, ICare and Goldmann applanation tonometry a comparative study. *Acta Ophthalmol* 2008;86(6):614-21.
36. Bandyopadhyay M, Raychaudhuri A, Lahiri SK, et al. Comparison of Goldmann applanation tonometry with the Tonopen for measuring intraocular pressure in a population-based glaucoma survey in rural West Bengal. *Ophthalmic Epidemiol* 2002;9(3):215-24.

37. Horowitz GS, Byles J, Lee J, D'Este C. Comparison of the Tono-Pen and Goldmann tonometer for measuring intraocular pressure in patients with glaucoma. *Clin Experiment Ophthalmol* 2004;32(6):584-9.
38. Salvetat ML, Zeppieri M, Tosoni C, Brusini P. Comparisons between Pascal dynamic contour tonometry, the TonoPen, and Goldmann applanation tonometry in patients with glaucoma. *Acta Ophthalmol Scand* 2007;85(3):272-9.
39. Rai S, Moster MR, Kesen M, et al. Level of disagreement between Proview phosphene tonometer and Goldmann applanation tonometer intraocular pressure readings. *J Glaucoma* 2005;14(2):120-3.
40. Brigatti L, Maguluri S. Reproducibility of self-measured intraocular pressure with the phosphene tonometer in patients with ocular hypertension and early to advanced glaucoma. *J Glaucoma* 2005;14(1):36-9.
41. Troost A, Specht K, Krummenauer F, et al. Deviations between transpalpebral tonometry using TGDC-01 and Goldmann applanation tonometry depending on the IOP level. *Graefes Arch Clin Exp Ophthalmol* 2005;243(9):853-8.
42. Lam DS, Leung DY, Chiu TY, et al. Pressure phosphene self-tonometry: a comparison with Goldmann tonometry in glaucoma patients. *Invest Ophthalmol Vis Sci* 2004;45(9):3131-6.
43. Rietveld E, van den Bremer DA, Volker-Dieben HJ. Clinical evaluation of the pressure phosphene tonometer in patients with glaucoma. *Br J Ophthalmol* 2005;89(5):537-9.
44. Holló G, Kóthy P, Vargha, P. Evaluation of continuous 24-hour intraocular pressure monitoring for assessment of prostaglandin induced pressure reduction in glaucoma. *J Glaucoma* 2014 Jan;23(1):e6-12.
45. Rahman ML, Bunce C, Healey PR, et al. Commingling analyses of central corneal thickness and adjusted intraocular pressure in an older Australian population. *Invest Ophthalmol Vis Sci* 2010;51(5):2512-8.
46. Duch S, Serra A, Castanera J, et al. Tonometry after laser in situ keratomileusis treatment. *J Glaucoma* 2001;10(4):261-5.
47. Palmerg P. Gonioscopy in: Ritch R, Shields MB, Krupin T, eds. *The glaucomas*. St Louis: CV Mosby1996; 455-69.
48. Spaeth GL. The normal development of the human anterior chamber angle: a new system of descriptive grading. *Trans Ophthalmol Soc U K* 1971;91:709-39.
49. Alward W. *Color atlas of gonioscopy*. London, Mosby1994.
50. Forbes M. Gonioscopy with corneal indentation. A method for distinguishing between appositional closure and synechial closure. *Arch Ophthalmol* 1966;76(4):488-92.
51. See JL, Chew PT, Smith SD, et al. Changes in anterior segment morphology in response to illumination and after laser iridotomy in Asian eyes: an anterior segment OCT study. *Br J Ophthalmol* 2007;91(11):1485-9.
52. Leung CK, Cheung CY, Li H, et al. Dynamic analysis of dark-light changes of the anterior chamber angle with anterior segment OCT. *Invest Ophthalmol Vis Sci* 2007;48(9):4116-22.
53. Denis P, Charpentier D, Berros P, Touameur S. Bilateral acute angle-closure glaucoma after dexfenfluramine treatment. *Ophthalmologica* 1995;209(4):223-4.
54. Quigley HA. The Iris Is a Sponge: A Cause of Angle Closure. *Ophthalmology* 2010;117(1):1-2.
55. Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. *Curr Opin Ophthalmol* 2007;18(2):129-33.
56. Kolker AE, Hetherington JTB-Ssd, therapy of the glaucomas. St Louis: CV Mosby. 1995.

57. Scheie HG. Width and pigmentation of the angle of the anterior chamber; a system of grading by gonioscopy. *AMA Arch Ophthalmol* 1957;58(4):510-2.
58. Shaffer RN. Gonioscopy anatomy of the angle of the anterior chamber of the eye. In) SRe, ed. In: *Stereoscopic manual of gonioscopy*. St. Louis, Mosby 1962.
59. Kanski JS, M. Glaukom. In: Kanski J. SMe, ed. In: *Lehrbuch der klinischen Ophthalmologie*. Stuttgart, New York Thieme, 1987.
60. Congdon NG, Spaeth GL, Augsburger J, et al. A proposed simple method for measurement in the anterior chamber angle: biometric gonioscopy. *Ophthalmology* 1999;106(11):2161-7.
61. Kaley-Landoy M, Day AC, Cordeiro MF, Migdal C. Optical coherence tomography in anterior segment imaging. *Acta Ophthalmol Scand* 2007;85(4):427-30.
62. Nolan W. Anterior segment imaging: identifying the landmarks. *Br J Ophthalmol* 2008;92(12):1575-6.
63. Wolffsohn JS, Davies LN. Advances in anterior segment imaging. *Curr Opin Ophthalmol* 2007;18(1):32-8.
64. Sakata LM, Lavanya R, Friedman DS, et al. Comparison of gonioscopy and anterior segment ocular coherence tomography in detecting angle closure in different quadrants of the anterior chamber angle. *Ophthalmology* 2008;115(5):769-74.
65. Dada T, Sihota R, Gadia R, et al. Comparison of anterior segment optical coherence tomography and ultrasound biomicroscopy for assessment of the anterior segment. *J Cataract Refract Surg* 2007;33(5):837-40.
66. Rabsilber TM, Khoramnia R, Auffarth GU. Anterior chamber measurements using Pentacam rotating Scheimpflug camera. *J Cataract Refract Surg* 2006;32(3):456-9.
67. Shukla S, Damji KF, Harasymowycz P, et al. Clinical features distinguishing angle closure from pseudoplateau versus plateau iris. *Br J Ophthalmol* 2008;92(3):340-4.
68. Friedman DS, Gazzard G, Min CB, et al. Age and sex variation in angle findings among normal Chinese subjects: a comparison of UBM, Scheimpflug, and gonioscopic assessment of the anterior chamber angle. *J Glaucoma* 2008;17(1):5-10.
69. Aptel F, Chiquet C, Beccat S, Denis P. Biometric evaluation of anterior chamber changes after physiologic pupil dilation using Pentacam and anterior segment optical coherence tomography. *Invest Ophthalmol Vis Sci* 2012;53(7):4005-10.
70. Tzamalís A, Pham DT, Wirbelauer C. Comparison of slit lamp-adapted optical coherence tomography features of fellow eyes of acute primary angle closure and eyes with open angle glaucoma. *Jpn J Ophthalmol* 2014.
71. Sng CC, Aquino MC, Liao J, et al. Pretreatment anterior segment imaging during acute primary angle closure: insights into angle closure mechanisms in the acute phase. *Ophthalmology* 2014;121(1):119-25.
72. Theelen T, Hoyng CB. A prospective, comparative, observational study on optical coherence tomography of the anterior eye segment. *Ophthalmologica* 2013;230(4):222-6.
73. Smith SD, Singh K, Lin SC, et al. Evaluation of the anterior chamber angle in glaucoma: a report by the american academy of ophthalmology. *Ophthalmology* 2013;120(10):1985-97.
74. Mak H, Xu G, Leung CK. Imaging the iris with swept-source optical coherence tomography: relationship between iris volume and primary angle closure. *Ophthalmology* 2013;120(12):2517-24.
75. Mishima K, Tomidokoro A, Suramethakul P, et al. Iridotrabeular contact observed

- using anterior segment three-dimensional OCT in eyes with a shallow peripheral anterior chamber. *Invest Ophthalmol Vis Sci* 2013;54(7):4628-35.
76. McKee H, Ye C, Yu M, et al. Anterior chamber angle imaging with swept-source optical coherence tomography: detecting the scleral spur, Schwalbe's Line, and Schlemm's Canal. *J Glaucoma* 2013;22(6):468-72.
  77. Matonti F, Chazalon E, Trichet E, et al. Dynamic gonioscopy using optical coherence tomography. *Ophthalmic Surg Lasers Imaging* 2012;43(6 Suppl):S90-6.
  78. Day AC, Garway-Heath DF, Broadway DC, et al. Spectral domain optical coherence tomography imaging of the aqueous outflow structures in normal participants of the EPIC-Norfolk Eye Study. *Br J Ophthalmol* 2013;97(2):189-95.
  79. Shabana N, Aquino MC, See J, et al. Quantitative evaluation of anterior chamber parameters using anterior segment optical coherence tomography in primary angle closure mechanisms. *Clin Experiment Ophthalmol* 2012;40(8):792-801.
  80. Sng CC, Foo LL, Cheng CY, et al. Determinants of anterior chamber depth: the Singapore Chinese Eye Study. *Ophthalmology* 2012;119(6):1143-50.
  81. Liu S, Yu M, Ye C, et al. Anterior chamber angle imaging with swept-source optical coherence tomography: an investigation on variability of angle measurement. *Invest Ophthalmol Vis Sci* 2011;52(12):8598-603.
  82. Lee KS, Sung KR, Kang SY, et al. Residual anterior chamber angle closure in narrow-angle eyes following laser peripheral iridotomy: anterior segment optical coherence tomography quantitative study. *Jpn J Ophthalmol* 2011;55(3):213-9.
  83. Fukuda S, Kawana K, Yasuno Y, Oshika T. Repeatability and reproducibility of anterior chamber volume measurements using 3-dimensional corneal and anterior segment optical coherence tomography. *J Cataract Refract Surg* 2011;37(3):461-8.
  84. Ursea R, Silverman RH. Anterior-segment imaging for assessment of glaucoma. *Expert Rev Ophthalmol* 2010;5(1):59-74.
  85. Dinc UA, Gorgun E, Oncel B, et al. Assessment of anterior chamber depth using Visante optical coherence tomography, slitlamp optical coherence tomography, IOL Master, Pentacam and Orbscan IIz. *Ophthalmologica* 2010;224(6):341-6.
  86. Pekmezci M, Porco TC, Lin SC. Anterior segment optical coherence tomography as a screening tool for the assessment of the anterior segment angle. *Ophthalmic Surg Lasers Imaging* 2009;40(4):389-98.
  87. See JL. Imaging of the anterior segment in glaucoma. *Clin Experiment Ophthalmol* 2009;37(5):506-13.
  88. Liu S, Li H, Dorairaj S, et al. Assessment of scleral spur visibility with anterior segment optical coherence tomography. *J Glaucoma* 2010;19(2):132-5.
  89. Yip LW, Sothornwit N, Berkowitz J, Mikelberg FS. A comparison of interocular differences in patients with pigment dispersion syndrome. *J Glaucoma* 2009;18(1):1-5.
  90. Jonas JB, Gusek GC, Naumann GO. Optic disc morphometry in chronic primary open-angle glaucoma. I. Morphometric intrapapillary characteristics. *Graefes Arch Clin Exp Ophthalmol* 1988;226(6):522-30.
  91. Tuulonen A, Airaksinen PJ. Initial glaucomatous optic disk and retinal nerve fiber layer abnormalities and their progression. *Am J Ophthalmol* 1991;111(4):485-90.
  92. Pederson JE, Anderson DR. The mode of progressive disc cupping in ocular hypertension and glaucoma. *Arch Ophthalmol* 1980;98(3):490-5.
  93. Zeyen TG, Caprioli J. Progression of disc and field damage in early glaucoma. *Arch Ophthalmol* 1993;111(1):62-5.

94. Spaeth GL. Development of glaucomatous changes of the optic nerve. In: (eds) PK, ed. Varma, R, Spaeth, GL: The optic nerve in glaucoma. Philadelphia: J.B. Lippincott, 1993.
95. Airaksinen PJ, Tuulonen A, Alanko HI. Rate and pattern of neuroretinal rim area decrease in ocular hypertension and glaucoma. *Arch Ophthalmol* 1992;110(2):206-10.
96. Hoyt WF, Frisen L, Newman NM. Fundoscopy of nerve fiber layer defects in glaucoma. *Invest Ophthalmol* 1973;12(11):814-29.
97. Jonas JB, Nguyen NX, Naumann GO. The retinal nerve fiber layer in normal eyes. *Ophthalmology* 1989;96(5):627-32.
98. Airaksinen PJ, Drance SM, Douglas GR, et al. Visual field and retinal nerve fiber layer comparisons in glaucoma. *Arch Ophthalmol* 1985;103(2):205-7.
99. Healey PR, Mitchell P, Smith W, Wang JJ. Optic disc hemorrhages in a population with and without signs of glaucoma. *Ophthalmology* 1998;105(2):216-23.
100. Budenz DL, Anderson DR, Feuer WJ, et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. *Ophthalmology* 2006;113(12):2137-43.
101. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. *Ophthalmology* 2007;114(11):1965-72.
102. Uhler TA, Piltz-Seymour J. Optic disc hemorrhages in glaucoma and ocular hypertension: implications and recommendations. *Curr Opin Ophthalmol* 2008;19(2):89-94.
103. Bengtsson B, Leske MC, Yang Z, Heijl A. Disc hemorrhages and treatment in the early manifest glaucoma trial. *Ophthalmology* 2008;115(11):2044-8.
104. Jonas JB, Nguyen XN, Gusek GC, Naumann GO. Parapapillary chorioretinal atrophy in normal and glaucoma eyes. I. Morphometric data. *Invest Ophthalmol Vis Sci* 1989;30(5):908-18.
105. Teng CC, De Moraes CG, Prata TS, et al. Beta-Zone parapapillary atrophy and the velocity of glaucoma progression. *Ophthalmology* 2010;117(5):909-15.
106. Teng CC, De Moraes CG, Prata TS, et al. The region of largest beta-zone parapapillary atrophy area predicts the location of most rapid visual field progression. *Ophthalmology* 2011;118(12):2409-13.
107. See JL, Nicolela MT, Chauhan BC. Rates of neuroretinal rim and peripapillary atrophy area change: a comparative study of glaucoma patients and normal controls. *Ophthalmology* 2009;116(5):840-7.
108. Jonas JB, Gusek GC, Naumann GO. Optic disc, cup and neuroretinal rim size, configuration and correlations in normal eyes. *Invest Ophthalmol Vis Sci* 1988;29(7):1151-8.
109. Healey PR, Mitchell P, Smith W, Wang JJ. Relationship between cup-disc ratio and optic disc diameter: the Blue Mountains Eye Study. *Aust N Z J Ophthalmol* 1997;25 Suppl 1:S99-101.
110. Heijl A, Molder H. Optic disc diameter influences the ability to detect glaucomatous disc damage. *Acta Ophthalmol (Copenh)* 1993;71(1):122-9.
111. Medeiros FA, Zangwill LM, Bowd C, Weinreb RN. Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma. *Arch Ophthalmol* 2004;122(6):827-37.
112. Strouthidis NG, Scott A, Peter NM, Garway-Heath DF. Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement. *Invest Ophthalmol Vis Sci* 2006;47(7):2904-10.
113. Leung CK, Liu S, Weinreb RN, et al. Evaluation of retinal nerve fiber layer progression in glaucoma a prospective analysis with neuroretinal rim and visual field progression. *Ophthalmology* 2011;118(8):1551-7.

114. Wollstein G, Garway-Heath DF, Fontana L, Hitchings RA. Identifying early glaucomatous changes. Comparison between expert clinical assessment of optic disc photographs and confocal scanning ophthalmoscopy. *Ophthalmology* 2000;107(12):2272-7.
115. Strouthidis NG, Garway-Heath DF. New developments in Heidelberg retina tomograph for glaucoma. *Curr Opin Ophthalmol* 2008;19(2):141-8.
116. Oddone F, Centofanti M, Rossetti L, et al. Exploring the Heidelberg Retinal Tomograph 3 diagnostic accuracy across disc sizes and glaucoma stages: a multicenter study. *Ophthalmology* 2008;115(8):1358-65, 65 e1-3.
117. Mai TA, Reus NJ, Lemij HG. Diagnostic accuracy of scanning laser polarimetry with enhanced versus variable corneal compensation. *Ophthalmology* 2007;114(11):1988-93.
118. Leung CK, Yu M, Weinreb RN, et al. Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: patterns of retinal nerve fiber layer progression. *Ophthalmology* 2012;119(9):1858-66.
119. Sung KR, Sun JH, Na JH, et al. Progression detection capability of macular thickness in advanced glaucomatous eyes. *Ophthalmology* 2012;119(2):308-13.
120. Araie M. Test-retest variability in structural parameters measured with glaucoma imaging devices. *Jpn J Ophthalmol* 2013;57(1):1-24.
121. Aulhorn EH, H. Early visual field defects in glaucoma. In: Leydhecker W, ed. *Glaucoma Tutzing Symposium*. Basel, Switzerland 1966.
122. Morales J, Weitzman ML, Gonzalez de la Rosa M. Comparison between Tendency-Oriented Perimetry (TOP) and octopus threshold perimetry. *Ophthalmology* 2000;107(1):134-42.
123. Shah NN, Bowd C, Medeiros FA, et al. Combining structural and functional testing for detection of glaucoma. *Ophthalmology* 2006;113(9):1593-602.
124. Sample PA, Medeiros FA, Racette L, et al. Identifying glaucomatous vision loss with visual-function-specific perimetry in the diagnostic innovations in glaucoma study. *Invest Ophthalmol Vis Sci* 2006;47(8):3381-9.
125. Tribble JR, Schultz RO, Robinson JC, Rothe TL. Accuracy of glaucoma detection with frequency-doubling perimetry. *Am J Ophthalmol* 2000;129(6):740-5.
126. van der Schoot J, Reus NJ, Colen TP, Lemij HG. The ability of short-wavelength automated perimetry to predict conversion to glaucoma. *Ophthalmology* 2010;117(1):30-4.
127. Bengtsson B, Heijl A. A visual field index for calculation of glaucoma rate of progression. *Am J Ophthalmol* 2008;145(2):343-53.
128. Chauhan BC, Garway-Heath DF, Goni FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. *Br J Ophthalmol* 2008;92(4):569-73.
129. Brusini P, Filacorda S. Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma. *J Glaucoma* 2006;15(1):40-6.
130. Ng M, Sample PA, Pascual JP, et al. Comparison of visual field severity classification systems for glaucoma. *J Glaucoma* 2012;21(8):551-61.
131. Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. *Ophthalmology* 1999;106(11):2144-53.
132. Mills RP, Budenz DL, Lee PP, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. *Am J Ophthalmol* 2006;141(1):24-30.
133. Hodapp E, Parrish RKL, Anderson DR. *Clinical decisions in glaucoma*. St Louis: The CV Mosby Co, 1993.